

Financial news for CLVS dated on 2020-06-10: Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer

Financial news for CLVS dated on 2020-06-08: Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.

Financial news for CLVS dated on 2020-05-29: The Daily Biotech Pulse: ASCO Presentations Begin, Altimimmune Pops On Insider Buying, Immuteq Gets R&D Grant

Financial news for CLVS dated on 2020-05-28: Clovis Oncology Reports New Recommendations For Rubraca Tablets In Updated National Comprehensive Cancer Network Guideliness

Financial news for CLVS dated on 2020-05-27: CORRECTION: Clovis Oncology Will Not Be Presenting Initial Phase 1b/2 Data For Lucitanib With Opdivo At ASCO This Weekend; Earlier Headline Incorrectly Suggested This Event Would Be Upcoming This Week

Financial news for CLVS dated on 2020-05-27: Clovis Oncology Option Alert: Jul 17 \$10 Calls at the Ask: 526 @ \$0.401 vs 4747 OI; Ref=\$6.46

Financial news for CLVS dated on 2020-05-22: HC Wainwright & Co. Reiterates Buy on Clovis Oncology, Lowers Price Target to \$29

Financial news for CLVS dated on 2020-05-21: Clovis Oncology Shares Spike To Session High, Up 1%; Traders Circulate Word Rubraca Added To National Comprehensive Cancer Networks To Prostate Cancer Guidelines

Financial news for CLVS dated on 2020-05-20: SVB Leerink Maintains Underperform on Clovis Oncology, Lowers Price Target to \$4

Financial news for CLVS dated on 2020-05-20: 61 Biggest Movers From Yesterday

Financial news for CLVS dated on 2020-05-19: Why Clovis Oncology's Stock Is Trading Lower Today

Financial news for CLVS dated on 2020-05-19: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLVS dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for CLVS dated on 2020-05-19: 28 Stocks Moving in Tuesday's Pre-Market Session

Financial news for CLVS dated on 2020-05-18: Clovis Oncology P:rices 11M Share Public Offering of Common Stock @\$8.05/Share

Financial news for CLVS dated on 2020-05-18: 6 Stocks Moving In Monday's After-Hours Session

Financial news for CLVS dated on 2020-05-18: Clovis Oncology shares are trading lower after the company announced a common stock offering of \$85 million shares.

Financial news for CLVS dated on 2020-05-18: Clovis Oncology AnnouncesA Common Stock Offering Of \$85 Million Shares

Financial news for CLVS dated on 2020-05-18: HC Wainwright & Co. Maintains Buy on Clovis Oncology, Raises Price Target to \$33

Financial news for CLVS dated on 2020-05-15: Why Clovis Oncology's Stock Spiked Higher Today

Financial news for CLVS dated on 2020-05-15: Clovis Oncology shares are trading higher after the company announced the FDA has approved its Rubraca tablets for the treatment of adult patients with a deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.

Financial news for CLVS dated on 2020-05-15: Clovis Oncology Shares Spike To Session High, Up 8.5%; Traders Circulate FDA Access Data Link For Co.'s Rubraca

Financial news for CLVS dated on 2020-05-15: The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO

Financial news for CLVS dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for CLVS dated on 2020-05-07: Shares of several healthcare companies are trading higher amid continued economic optimism as some US states ease lockdown restrictions. While jobless claims came in worse than estimates, figures were lower than in prior weeks.

Financial news for CLVS dated on 2020-05-06: 58 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLVS dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for CLVS dated on 2020-05-06: Benzinga Pro's Top 5 Stocks To Watch for Wed., May 6, 2020: SNY, GRUB, CLVS, NTDOY, FDS

Financial news for CLVS dated on 2020-05-06: 19 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2020-05-06: Clovis Oncology shares are trading higher after the company reported better-than-expected Q1 sales results.

Financial news for CLVS dated on 2020-05-06: H.C. Wainwright Reiterates Buy on Clovis Oncology, Raises Price Target to \$29

Financial news for CLVS dated on 2020-05-05: Clovis Oncology shares are trading higher after the company reported better-than-expected Q1 sales results.

Financial news for CLVS dated on 2020-05-05: Clovis Oncology Q1 EPS \$(1.390) Misses \$(1.280) Estimate, Sales \$42.564M Beat \$41.240M Estimate

Financial news for CLVS dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for CLVS dated on 2020-05-03: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for CLVS dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for CLVS dated on 2020-04-27: Benzinga's Top Upgrades, Downgrades For April 27, 2020

Financial news for CLVS dated on 2020-04-27: Clovis Oncology shares are trading lower after SVB Leerink downgraded the stock from Market Perform to Underperform and announced a price target of \$5 per share.

Financial news for CLVS dated on 2020-04-27: SVB Leerink Downgrades Clovis Oncology to Underperform, Announces \$5 Price Target

Financial news for CLVS dated on 2020-04-23: Clovis Oncology Option Alert: May 8 \$12.5 Calls Sweep (5) near the Ask: 300 @ \$0.35 vs 69 OI; Earnings 5/5 After Close Ref=\$9.47

Financial news for CLVS dated on 2020-04-21: 78 Biggest Movers From Yesterday

Financial news for CLVS dated on 2020-04-20: 54 Stocks Moving In Monday's Mid-Day Session

Financial news for CLVS dated on 2020-04-20: Clovis Oncology Option Alert: May 15 \$10 Calls Sweep (3) near the Ask: 453 @ \$1.65 vs 4278 OI; Earnings 5/5 Before Open [est] Ref=\$9.9

Financial news for CLVS dated on 2020-04-17: 12 Short Squeeze Candidates To Watch

Financial news for CLVS dated on 2020-04-17: Clovis Oncology Option Alert: Fri \$8 Calls Sweep (10) near the Ask: 2007 @ \$0.1 vs 12205 OI; Earnings 5/5 Before Open [est] Ref=\$8.06

Financial news for CLVS dated on 2020-04-13: Clovis Oncology Option Alert: Jul 17 \$9 Calls Sweep (10) near the Ask: 325 @ \$1.5 vs 3990 OI; Earnings 5/5 Before Open [est] Ref=\$7.14

Financial news for CLVS dated on 2020-04-09: Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca

Financial news for CLVS dated on 2020-04-09: Benzinga's Top Upgrades, Downgrades For April 9, 2020

Financial news for CLVS dated on 2020-04-09: Cloves Oncology shares are trading lower

after Bank Of America downgraded the stock from Neutral to Underperform and announced a price target of \$6 per share.

Financial news for CLVS dated on 2020-04-09: B of A Securities Downgrades Clovis Oncology to Underperform, Announces \$6 Price Target

Financial news for CLVS dated on 2020-03-30: 90 Biggest Movers From Friday

Financial news for CLVS dated on 2020-03-27: Clovis Oncology shares are trading higher. Not seeing any company-specific news to justify the price action.

Financial news for CLVS dated on 2020-03-26: Shares of several healthcare companies are trading higher following Senate passage of a \$2 trillion economic stimulus package, which has lifted stocks across sectors.

Financial news for CLVS dated on 2020-03-17: 110 Biggest Movers From Yesterday

Financial news for CLVS dated on 2020-03-16: 95 Stocks Moving In Monday's Mid-Day Session

Financial news for CLVS dated on 2020-03-16: Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for CLVS dated on 2020-03-16: 20 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2020-03-16: 22 Stocks Moving in Monday's Pre-Market Session

Financial news for CLVS dated on 2020-03-09: 52 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2020-03-05: 28 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for CLVS dated on 2020-03-04: Clovis Oncology Option Alert: Mar 20 \$7.5 Puts at the Bid: 5000 @ \$0.7 vs 701 OI; Ref=\$7.87

Financial news for CLVS dated on 2020-03-02: Clovis Oncology Announces Availability and Reimbursement for Rubraca Tablets for Women with Relapsed Ovarian Cancer in Spain

Financial news for CLVS dated on 2020-02-27: Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.

Financial news for CLVS dated on 2020-02-26: 80 Biggest Movers From Yesterday

Financial news for CLVS dated on 2020-02-25: 55 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLVS dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for CLVS dated on 2020-02-25: Clovis Oncology shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Financial news for CLVS dated on 2020-02-25: 77 Biggest Movers From Yesterday

Financial news for CLVS dated on 2020-02-24: 14 Stocks Moving In Monday's After-Hours Session

Financial news for CLVS dated on 2020-02-24: Clovis Oncology shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Financial news for CLVS dated on 2020-02-24: Clovis Oncology Q4 EPS \$(1.81) Misses \$(1.71) Estimate, Sales \$39.307M Beat \$38.97M Estimate

Financial news for CLVS dated on 2020-02-24: 55 Stocks Moving In Monday's Mid-Day Session

Financial news for CLVS dated on 2020-02-24: Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.

Financial news for CLVS dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for CLVS dated on 2020-02-20: 78 Biggest Movers From Yesterday

Financial news for CLVS dated on 2020-02-19: Clovis Oncology Option Alert: Apr 17 \$10 Calls at the Ask: 3000 @ \$2.3 vs 25074 OI; Earnings 2/24 After Close Ref=\$10.17

Financial news for CLVS dated on 2020-02-19: Clovis Oncology shares are trading higher after the company's CEO and President acquired 50,000 shares at an average price of \$9.71 per share. When an insider acquires shares, the market may perceive it as a sign of confidence in the company's outlook.

Financial news for CLVS dated on 2020-02-14: Clovis Oncology Option Alert: Apr 17 \$15 Calls Sweep (13) near the Ask: 1000 @ \$0.451 vs 6949 OI; Earnings 2/24 After Close Ref=\$9.0288

Financial news for CLVS dated on 2020-02-13: Clovis Oncology 13G From State Street Shows 6.68% Stake

Financial news for CLVS dated on 2020-02-06: 4 Stocks Looking Higher During Earnings Season

Financial news for CLVS dated on 2020-02-05: Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.

Financial news for CLVS dated on 2020-02-03: 61 Stocks Moving In Monday's Mid-Day Session

Financial news for CLVS dated on 2020-02-03: 10 Biotechnology Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2020-02-03: 18 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2020-02-03: 30 Stocks Moving in Monday's Pre-Market Session

Financial news for CLVS dated on 2020-02-03: Clovis Oncology shares are trading higher after the company announced Rubraca tablets will now be available and reimbursed in France for women with relapsed ovarian cancer.

Financial news for CLVS dated on 2020-02-03: Clovis Oncology Announces Availability and Reimbursement for Rubraca Tablets for Women with Relapsed Ovarian Cancer in France

Financial news for CLVS dated on 2020-01-30: 90 Biggest Movers From Yesterday

Financial news for CLVS dated on 2020-01-29: 62 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLVS dated on 2020-01-29: Clovis Oncology shares are trading higher. Not currently seeing any company-specific news from today.

Financial news for CLVS dated on 2020-01-23: B of A Securities Maintains Neutral on Clovis Oncology, Raises Price Target to \$10

Financial news for CLVS dated on 2020-01-23: Clovis Oncology Option Alert: Feb 7 \$11 Calls Sweep (9) near the Ask: 778 @ \$0.3 vs 74 OI; Earnings 2/24 After Close Ref=\$9.435

Financial news for CLVS dated on 2020-01-23: Clovis Oncology Option Alert: Feb 21 \$11 Calls at the Ask: 700 @ \$0.451 vs 5747 OI; Earnings 2/24 After Close Ref=\$9.32

Financial news for CLVS dated on 2020-01-22: 98 Biotechnology Stocks Moving In Wednesday's Session

Financial news for CLVS dated on 2020-01-22: 116 Healthcare Stocks Moving In Wednesday's Session

Financial news for CLVS dated on 2020-01-21: Clovis Oncology Option Alert: Jan, 2021 \$15 Calls at the Ask: 1991 @ \$2.5 vs 2268 OI; Earnings 2/24 After Close Ref=\$9.515

Financial news for CLVS dated on 2020-01-16: 75 Biggest Movers From Yesterday

Financial news for CLVS dated on 2020-01-15: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLVS dated on 2020-01-15: Clovis Oncology Option Alert: Jul 17 \$6 Puts Sweep (16) near the Bid: 890 @ \$1.1 vs 33 OI; Earnings 2/24 After Close

Ref=\$10.11

Financial news for CLVS dated on 2020-01-15: FDA Grants Priority Review Designation For Clovis Oncology's Rubraca Label Expansion

Financial news for CLVS dated on 2020-01-15: Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Reports Mixed Q4 Results

Financial news for CLVS dated on 2020-01-15: Clovis Oncology shares are trading higher after Rubraca was granted FDA priority reviewed for advanced prostate cancer.

Financial news for CLVS dated on 2020-01-15: 34 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2020-01-15: Clovis Oncology's Rubraca Granted FDA Priority Review For Advanced Prostate Cancer

Financial news for CLVS dated on 2020-01-09: 54 Biggest Movers From Yesterday

Financial news for CLVS dated on 2020-01-08: Clovis Oncology shares are trading higher potentially on a rebound after the stock dropped roughly 11% after the company gave preliminary Q4 and FY19 sales guidance for Rubraca. Not seeing any news to justify the price action.

Financial news for CLVS dated on 2020-01-08: Clovis Oncology Option Alert: Apr 17 \$15 Calls at the Ask: 1000 @ \$0.43 vs 5494 OI; Earnings 2/25 Before Open [est]  
Ref=\$8.1549

Financial news for CLVS dated on 2020-01-07: Clovis Oncology shares are trading lower after the company issued its preliminary Q4 and FY19 sales guidance.

Financial news for CLVS dated on 2020-01-07: Clovis Oncology Sees Prelim. Q4 Rubraca Sales \$38.3M-\$39.3M, FY19 Rubraca Sales \$142.0-\$143.0M

Financial news for CLVS dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for CLVS dated on 2019-12-20: Clovis Oncology Option Alert: Fri \$12 Puts at the Bid: 4000 @ \$0.801 vs 9670 OI; Ref=\$11.05

Financial news for CLVS dated on 2019-12-17: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLVS dated on 2019-12-17: 19 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLVS dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

Financial news for CLVS dated on 2019-12-17: 30 Stocks Moving in Tuesday's Pre-Market Session

Financial news for CLVS dated on 2019-12-16: Clovis Oncology Files For \$250M Mixed Shelf Offering

Financial news for CLVS dated on 2019-12-16: Clovis Oncology Option Alert: Apr 17 \$4 Calls Sweep (2) near the Bid: 13000 @ \$8.5 vs 287 OI; Ref=\$12.66

Financial news for CLVS dated on 2019-12-16: Clovis Oncology Highlights Presentation Of first Clinical Experience With FAP-2286 In Named-Patient Use

Financial news for CLVS dated on 2019-12-13: Clovis Oncology Option Alert: Jul 17 \$13 Calls Sweep (2) near the Ask: 2500 @ \$3.275 vs 233 OI; Ref=\$12.82

Financial news for CLVS dated on 2019-12-13: 20 Stocks Moving in Friday's Pre-Market Session

Financial news for CLVS dated on 2019-12-12: Clovis Oncology Option Alert: Dec 20 \$15 Calls Sweep (2) above Ask!: 1000 @ \$0.625 vs 5111 OI; Ref=\$13.3

Financial news for CLVS dated on 2019-12-12: Clovis Oncology Option Alert: Jan 17 \$10 Calls Sweep (4) near the Ask: 580 @ \$3.101 vs 7786 OI; Ref=\$12.57

Financial news for CLVS dated on 2019-12-11: 32 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2019-12-11: 66 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-12-10: Clovis Oncology Option Alert: Dec 20 \$12 Puts at the Bid: 4000 @ \$1.15 vs 6115 OI; Ref=\$12.39

Financial news for CLVS dated on 2019-12-10: Clovis Oncology shares are trading higher on continued momentum after Jim Cramer, on CNBC's "Mad Money," said he thinks the company is a good spec.

Financial news for CLVS dated on 2019-12-10: 41 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLVS dated on 2019-12-10: 80 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-12-09: Clovis Oncology Option Alert: Apr 17 \$8 Puts at the Bid: 1600 @ \$2.25 vs 3998 OI; Ref=\$10.3913

Financial news for CLVS dated on 2019-12-09: Clovis Oncology shares are trading higher after Jim Cramer, on CNBC's "Mad Money," said he thinks the company is a good spec.

Financial news for CLVS dated on 2019-12-09: Cramer Gives His Take On Bank Of America, BlackBerry And More

Financial news for CLVS dated on 2019-12-09: 74 Biggest Movers From Friday

Financial news for CLVS dated on 2019-12-06: 55 Stocks Moving In Friday's Mid-Day Session

Financial news for CLVS dated on 2019-12-06: Clovis Oncology shares are trading higher in sympathy with the overall market after the U.S. added 266,000 jobs in November, beating expectations and lowering the unemployment rate to 3.5%.

Financial news for CLVS dated on 2019-12-06: 75 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-12-05: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for CLVS dated on 2019-12-05: Clovis Oncology shares are trading lower. Not currently seeing any company-specific news to explain sell off.

Financial news for CLVS dated on 2019-12-04: Clovis Oncology shares are trading higher. Strength may be due to a potential rebound after the stock fell roughly 25% yesterday.

Financial news for CLVS dated on 2019-12-04: 12 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2019-12-04: 63 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-12-03: Clovis Oncology Option Alert: Jan 17 \$15 Calls Sweep (12) near the Ask: 500 @ \$2.45 vs 4318 OI; Ref=\$13.85

Financial news for CLVS dated on 2019-12-03: Clovis Oncology Option Alert: Jan 17 \$25 Calls Sweep (23) near the Ask: 585 @ \$0.794 vs 2858 OI; Ref=\$14.13

Financial news for CLVS dated on 2019-12-03: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLVS dated on 2019-12-03: Clovis Oncology shares are trading lower following recent upward momentum. Weakness potentially related to investor doubts over recent M&A speculation.

Financial news for CLVS dated on 2019-12-03: 19 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLVS dated on 2019-12-03: 75 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-12-02: Clovis Oncology shares are trading higher on seemingly no company-specific news. NOTE: Since November 5th the stock has rallied roughly 350%.

Financial news for CLVS dated on 2019-12-02: 10 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2019-12-02: 52 Biggest Movers From Friday

Financial news for CLVS dated on 2019-11-29: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for CLVS dated on 2019-11-29: Clovis Oncology shares are trading

higher. Not seeing any news to justify the price action.

Financial news for CLVS dated on 2019-11-29: 52 Biggest Movers From Wednesday

Financial news for CLVS dated on 2019-11-27: Clovis Oncology Option Alert: Jan 17 \$15 Calls at the Ask: 704 @ \$1.591 vs 1155 OI; Ref=\$12.39

Financial news for CLVS dated on 2019-11-27: Clovis Oncology shares are trading higher. Not seeing any news to justify the price action.

Financial news for CLVS dated on 2019-11-26: Clovis Oncology shares are trading on above-average volume. NOTE: The stock has rallied approximately 44% over the past 5 trading sessions.

Financial news for CLVS dated on 2019-11-26: Clovis Oncology Option Alert: Apr 17 \$7 Puts Sweep (3) near the Bid: 654 @ \$1.601 vs 12408 OI; Ref=\$11.42

Financial news for CLVS dated on 2019-11-26: 14 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLVS dated on 2019-11-26: 45 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-11-25: Clovis Oncology shares are trading higher on above-average volume. Not seeing any news to justify the price action.

Financial news for CLVS dated on 2019-11-25: Clovis Oncology Option Alert: Apr 17 \$6 Puts Sweep (5) near the Bid: 500 @ \$1.051 vs 3440 OI; Ref=\$9.3348

Financial news for CLVS dated on 2019-11-25: 36 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2019-11-22: 3 Momentum Stocks To Watch Post-Earnings

Financial news for CLVS dated on 2019-11-22: Clovis Oncology Option Alert: Dec 20 \$6 Calls Sweep (3) near the Ask: 971 @ \$2.484 vs 4367 OI; Ref=\$8.4

Financial news for CLVS dated on 2019-11-22: Clovis Oncology shares are trading higher. Not seeing any news to justify the price action.

Financial news for CLVS dated on 2019-11-22: 66 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-11-21: Clovis Oncology shares are trading higher. Not seeing any news to justify the price action. NOTE: The stock has rallied approximately 116% over the past month.

Financial news for CLVS dated on 2019-11-21: 22 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for CLVS dated on 2019-11-21: 63 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-11-20: Clovis Oncology shares are trading lower in sympathy with weakness in the overall market after it was reported phase one of the US-China trade deal may not happen this year.

Financial news for CLVS dated on 2019-11-20: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLVS dated on 2019-11-20: 33 Stocks Moving in Wednesday's Pre-Market Session

Financial news for CLVS dated on 2019-11-20: 77 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-11-19: Clovis Oncology Option Alert: Dec 20 \$10 Calls at the Ask: 974 @ \$0.41 vs 904 OI; Ref=\$7.58

Financial news for CLVS dated on 2019-11-19: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLVS dated on 2019-11-19: Clovis Oncology shares are trading higher. Not seeing any news to justify the price action.

Financial news for CLVS dated on 2019-11-19: Benzinga's Top Upgrades, Downgrades For November 19, 2019

Financial news for CLVS dated on 2019-11-19: 8 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLVS dated on 2019-11-19: 28 Stocks Moving in Tuesday's Pre-Market Session

Financial news for CLVS dated on 2019-11-19: Evercore ISI Group Downgrades Clovis Oncology to In-Line, Announces \$8 Price Target

Financial news for CLVS dated on 2019-11-19: 72 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-11-14: 19 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for CLVS dated on 2019-11-14: 81 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-11-13: 54 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLVS dated on 2019-11-13: Clovis Oncology shares are trading higher after the company announced that the Italian Medicines Agency has approved the company's Rucaparib for reimbursement in Italy.

Financial news for CLVS dated on 2019-11-11: 80 Biggest Movers From Friday

Financial news for CLVS dated on 2019-11-08: Mid-Afternoon Market Update: Sientra Rises Following Q3 Results; AnaptysBio Shares Slide

Financial news for CLVS dated on 2019-11-08: 65 Stocks Moving In Friday's Mid-Day Session

Financial news for CLVS dated on 2019-11-08: Mid-Day Market Update: Modine Manufacturing Drops After Q2 Results; Ubiquiti Shares Climb

Financial news for CLVS dated on 2019-11-08: Clovis Oncology shares are trading higher following Q3 results. The company reported better-than-expected EPS and sales and a 42% year-over-year drop in cash burn.

Financial news for CLVS dated on 2019-11-08: 94 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-11-07: 75 Stocks Moving In Thursday's Mid-Day Session

Financial news for CLVS dated on 2019-11-07: Clovis Oncology shares are trading higher following Q3 results. The company reported better-than-expected EPS and sales and a 42% year-over-year drop in cash burn.

Financial news for CLVS dated on 2019-11-07: Clovis Oncology Earlier Reported Q3 EPS \$(1.85) Beats \$(1.89) Estimate, Sales \$37.603M Beat \$35.84M Estimate

Financial news for CLVS dated on 2019-11-07: 23 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for CLVS dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for CLVS dated on 2019-11-04: 24 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for CLVS dated on 2019-11-01: Clovis Oncology shares are trading higher on seemingly no company-specific news.

Financial news for CLVS dated on 2019-10-29: 46 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-10-28: Clovis Oncology Option Alert: Jan, 2021 \$13 Calls at the Bid: 20000 @ \$0.5 vs 20487 OI; Earnings 11/7 Before Open Ref=\$3.73

Financial news for CLVS dated on 2019-10-28: Clovis Oncology Shares Resume Trade, Continue Higher, Up 26.7% For Session

Financial news for CLVS dated on 2019-10-28: Clovis Oncology shares are trading higher on seemingly no company-specific news. The company has experienced heavy spike in volume.

Financial news for CLVS dated on 2019-10-28: Clovis Oncology Shares Halted On Circuit Breaker, Up 23%, On Very Heavy Spike In Volume

Financial news for CLVS dated on 2019-10-28: Clovis Oncology Option Alert: Nov 15 \$4 Calls Sweep (30) near the Ask: 658 @ \$0.401 vs 3054 OI; Earnings 11/7 Before Open Ref=\$3.51



Financial news for CLVS dated on 2019-10-28: Stocks That Hit 52-Week Lows On Monday

Financial news for CLVS dated on 2019-10-23: Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption

Financial news for CLVS dated on 2019-10-21: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for CLVS dated on 2019-10-21: 26 Stocks Moving in Monday's Pre-Market Session

Financial news for CLVS dated on 2019-10-18: 32 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for CLVS dated on 2019-10-18: 48 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-10-17: Clovis Oncology shares are trading higher on seemingly no company-specific news.

Financial news for CLVS dated on 2019-10-16: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wed., October 16, 2019

Financial news for CLVS dated on 2019-10-15: Stocks That Hit 52-Week Lows On Tuesday

Financial news for CLVS dated on 2019-10-15: The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings

Financial news for CLVS dated on 2019-10-11: Clovis Oncology Reports Rubraca Now Available In England For Women With Relapse Ovarian Cancer

Financial news for CLVS dated on 2019-10-11: The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

Financial news for CLVS dated on 2019-10-10: The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

Financial news for CLVS dated on 2019-10-09: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wed., October 09, 2019

Financial news for CLVS dated on 2019-10-09: Stocks That Hit 52-Week Lows On Wednesday

Financial news for CLVS dated on 2019-10-09: The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug

Financial news for CLVS dated on 2019-10-09: 42 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-10-08: Clovis Oncology shares are trading lower after Goldman Sachs maintained its Sell rating on the stock and lowered the price target from \$13 to \$3 per share.

Financial news for CLVS dated on 2019-10-08: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLVS dated on 2019-10-08: Stocks That Hit 52-Week Lows On Tuesday

Financial news for CLVS dated on 2019-10-08: Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks

Financial news for CLVS dated on 2019-10-08: UPDATE: Goldman On Clovis Oncology Also Notes 'Given the diminished topline outlook and continuing investment in rucaparib label expansion, we see the high cash burn and convertible debt burden continuing to be overhangs on the stock'

Financial news for CLVS dated on 2019-10-08: UPDATE: Goldman Reiterates Sell On Clovis Oncology, Lowers Target To \$3 As Firm Sees 'risk to longer term consensus estimates that embed meaningful growth driven from Rubraca use in prostate cancer and frontline/combo use with PD-1s'

Financial news for CLVS dated on 2019-10-08: Goldman Sachs Maintains Sell on Clovis Oncology, Lowers Price Target to \$3

Financial news for CLVS dated on 2019-10-08: The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration

Financial news for CLVS dated on 2019-10-07: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Mon., October 07, 2019

Financial news for CLVS dated on 2019-10-07: Stocks That Hit 52-Week Lows Of Monday

Financial news for CLVS dated on 2019-10-02: Stocks That Hit 52-Week Lows On Wednesday

Financial news for CLVS dated on 2019-10-01: The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

Financial news for CLVS dated on 2019-09-30: Stocks That Hit 52-Week Lows On Monday

Financial news for CLVS dated on 2019-09-30: Clovis Oncology Early Sunday Highlighted Rubraca(r) (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019

Financial news for CLVS dated on 2019-09-29: The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear

Financial news for CLVS dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for CLVS dated on 2019-09-25: The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug

Financial news for CLVS dated on 2019-09-25: 58 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for CLVS dated on 2019-09-24: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLVS dated on 2019-09-24: Benzinga's Top Upgrades, Downgrades For September 24, 2019

Financial news for CLVS dated on 2019-09-24: Clovis Oncology shares are trading lower after SVB Leerink downgraded the stock from Outperform to Market Perform.

Financial news for CLVS dated on 2019-09-24: The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger

Financial news for CLVS dated on 2019-09-24: 14 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLVS dated on 2019-09-24: SVB Leerink Downgrades Clovis Oncology to Market Perform

Financial news for CLVS dated on 2019-09-23: Stocks That Hit 52-Week Lows On Monday

Financial news for CLVS dated on 2019-09-23: Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals for \$12M Upfront Plus Potential Milestones and Royalties

Financial news for CLVS dated on 2019-09-20: The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering

Financial news for CLVS dated on 2019-09-17: Clovis Oncology shares are trading lower. Shares fell more than 50% to below \$10 at the beginning of August following weak Q2 results and a senior notes offering. The stock has traded largely between \$5 and \$6 since then.

Financial news for CLVS dated on 2019-09-12: Clovis Oncology shares are trading lower after the company announced that three posters highlighting studies from the Rubraca clinical development program will be presented at the ESMO Congress 2019.

Financial news for CLVS dated on 2019-09-12: Clovis Oncology to Highlight Expanded Data from Rubraca TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019

Financial news for CLVS dated on 2019-09-11: Clovis Oncology Option Alert: Jan 17 \$6 Puts Sweep (2) below Bid!: 2000 @ \$1.326 vs 277 OI; Earnings 10/29 After Close [est] Ref=\$5.8245

Financial news for CLVS dated on 2019-09-11: 80 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-08-20: 22 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLVS dated on 2019-08-20: The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine

Financial news for CLVS dated on 2019-08-19: Clovis Oncology 13G Shows Whitebox Advisors Holds 7% Stake In Co.

Financial news for CLVS dated on 2019-08-19: Shares of several healthcare companies are trading higher on renewed hopes of a resolution to trade tensions between the US and China.

Financial news for CLVS dated on 2019-08-19: 60 Biggest Movers From Friday

Financial news for CLVS dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal

Financial news for CLVS dated on 2019-08-16: 41 Stocks Moving In Friday's Mid-Day Session

Financial news for CLVS dated on 2019-08-13: AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis

Financial news for CLVS dated on 2019-08-13: Benzinga's Top Upgrades, Downgrades For August 13, 2019

Financial news for CLVS dated on 2019-08-13: 10 Biggest Price Target Changes For Tuesday

Financial news for CLVS dated on 2019-08-13: 16 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLVS dated on 2019-08-13: 31 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLVS dated on 2019-08-13: Bank of America Downgrades Clovis Oncology to Neutral, Lowers Price Target to \$7

Financial news for CLVS dated on 2019-08-09: Clovis Oncology shares are trading lower after the company announced the pricing of \$250 million of convertible senior notes.

Financial news for CLVS dated on 2019-08-09: 31 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for CLVS dated on 2019-08-09: 52 Stocks Moving In Friday's Pre-Market Session

Financial news for CLVS dated on 2019-08-09: The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2

Financial news for CLVS dated on 2019-08-09: 110 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-08-08: 50 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for CLVS dated on 2019-08-08: 90 Stocks Moving In Thursday's Mid-Day Session

Financial news for CLVS dated on 2019-08-08: Clovis Oncology shares are trading lower after the company launched a \$225 million convertible debt offering.

Financial news for CLVS dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for CLVS dated on 2019-08-07: 42 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for CLVS dated on 2019-08-02: Stocks That Set New 52-Week Lows Friday Morning

Financial news for CLVS dated on 2019-08-02: Benzinga's Top Upgrades, Downgrades For August 2, 2019

Financial news for CLVS dated on 2019-08-02: Guggenheim Downgrades Clovis Oncology to Neutral

Financial news for CLVS dated on 2019-08-02: 100 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-08-01: 72 Stocks Moving In Thursday's Mid-Day Session

Financial news for CLVS dated on 2019-08-01: Stocks that Reached Yearly Lows Thursday Morning

Financial news for CLVS dated on 2019-08-01: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for CLVS dated on 2019-08-01: Clovis Oncology shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results.

Financial news for CLVS dated on 2019-08-01: Clovis Oncology Q2 EPS \$(2.27) Misses \$(1.71) Estimate, Sales \$32.98M Miss \$34.92M Estimate

Financial news for CLVS dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for CLVS dated on 2019-07-31: 42 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2019-07-29: Clovis Oncology Option Alert: Aug 16 \$13 Calls Sweep (2) above Ask!: 1000 @ \$0.325 vs 871 OI; Earnings 8/1 Before Open Ref=\$10.64

Financial news for CLVS dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for CLVS dated on 2019-07-26: Stocks That Managed to Breach 52-Week Lows Friday

Financial news for CLVS dated on 2019-07-02: Clovis Oncology shares are trading lower after its S-3 showed registration for about 1.48 million shares common stock offering by the selling of shareholders.

Financial news for CLVS dated on 2019-07-02: Clovis Oncology S-3 Shows Registration For ~1.48M Share Common Stock Offering Via Selling Shareholders

Financial news for CLVS dated on 2019-06-26: Clovis Oncology Option Alert: Jul 19 \$14 Calls Sweep (43) near the Ask: 964 @ \$0.551 vs 507 OI; Earnings 7/31 After Close [est] Ref=\$12.6999

Financial news for CLVS dated on 2019-06-25: 60 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for CLVS dated on 2019-06-17: Clovis Oncology Announces Agreement to Settle Lawsuit Filed By Antipodean Against Co, Certain Officers and Directors; Clovis to Pay to Antipodean \$4M in Cash, \$21M in Shares of Clovis Stock

Financial news for CLVS dated on 2019-06-11: Clovis Oncology Discloses Amended And Restated Certificate Of Incorporation To Increase Number Of Shares Of Common Stock Authorized For Issuance From 100M To 200M

Financial news for CLVS dated on 2019-06-07: The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

Financial news for CLVS dated on 2019-06-03: Clovis Oncology Option Alert: Jan, 2021 \$20 Calls Sweep (9) near the Ask: 500 @ \$4.8 vs 22898 OI; Earnings 7/31 After Close [est] Ref=\$15.21

Financial news for CLVS dated on 2019-06-01: Clovis Oncology Announces Expanded Rubraca Data from ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at #ASCO19

Financial news for CLVS dated on 2019-05-29: Clovis Oncology Option Alert: Jan, 2021 \$20 Calls at the Ask: 800 @ \$4.581 vs 20748 OI; Ref=\$15.1

Financial news for CLVS dated on 2019-05-29: Benzinga's Top Upgrades, Downgrades For May 29, 2019

Financial news for CLVS dated on 2019-05-29: Goldman Sachs Downgrades Clovis Oncology to Sell, Lowers Price Target to \$15 Price Target

Financial news for CLVS dated on 2019-05-24: Clovis Oncology Option Alert: Jan 17 \$20 Calls at the Ask: 3500 @ \$3.0 vs 187 OI; Ref=\$16.8002

Financial news for CLVS dated on 2019-05-24: Clovis Oncology Option Alert: Jan, 2021 \$20 Calls at the Ask: 20000 @ \$5.901 vs 207 OI; Ref=\$16.75

Financial news for CLVS dated on 2019-05-21: The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

Financial news for CLVS dated on 2019-05-16: Clovis Oncology Highlights 4 Abstracts At ASCO

Financial news for CLVS dated on 2019-05-07: The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

Financial news for CLVS dated on 2019-05-07: Clovis Oncology Q1 EPS \$(1.63) Beats \$(1.74) Estimate, Sales \$33.118M Beat \$32.24M Estimate

Financial news for CLVS dated on 2019-05-02: Clovis Oncology Enters Into Non-Dilutive Clinical Trial Financing With TPG Sixth Street Partners For Up To \$175M

Financial news for CLVS dated on 2019-04-16: 44 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-04-15: 34 Stocks Moving In Monday's Mid-Day Session

Financial news for CLVS dated on 2019-04-15: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2019-04-15: Clovis Oncology shares are trading lower after the company announced it would stop its Phase 2 ATLAS study of Rubraca.

Financial news for CLVS dated on 2019-04-02: UPDATE: Clovis Says Data 'suggest that Rubraca provides disease control with no new safety signals in 19 evaluable platinum-sensitive patients with germline BRCA1, germline or somatic BRCA2, or germline PALB2 mutations'

Financial news for CLVS dated on 2019-04-02: Clovis Oncology Reports Interim Results From Rubraca Phase 2 Study In Advanced Pancreatic Cancer, Nonclinical Data In Multiple Solid Tumor Types For Rucaparib, Lucitanib Presented At AACR Meeting

Financial news for CLVS dated on 2019-04-02: The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

Financial news for CLVS dated on 2019-03-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for CLVS dated on 2019-03-19: Clovis Oncology To Present At 2019 AACR Annual Meeting

Financial news for CLVS dated on 2019-03-08: Clovis Oncology Option Alert: Apr 18 \$30 Calls Sweep (2) near the Ask: 1750 @ \$2.175 vs 2555 OI; Earnings 5/7 After Close [est] Ref=\$27.2

Financial news for CLVS dated on 2019-03-04: Clovis Oncology Announces Availability of Rubraca Tablets for Women with Relapsed Ovarian Cancer in Germany

Financial news for CLVS dated on 2019-02-28: 84 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-02-27: 72 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLVS dated on 2019-02-26: Clovis Oncology Q4 EPS \$(1.88) Misses \$(1.73) Estimate, Sales \$30.351M Beat \$26.91M Estimate

Financial news for CLVS dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for CLVS dated on 2019-02-25: Clovis Oncology Option Alert: Mar 15 \$27 Calls Sweep (2) near the Ask: 900 @ \$1.925 vs 2664 OI; Earnings 2/26 Before Open Ref=\$25.78

Financial news for CLVS dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for CLVS dated on 2019-02-19: Clovis Oncology Option Alert: Mar 15 \$27 Calls at the Ask: 1300 @ \$1.65 vs 737 OI; Earnings 2/26 Before Open Ref=\$24.62

Financial news for CLVS dated on 2019-02-19: Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies

Financial news for CLVS dated on 2019-02-15: Centers For Medicaid, Medicare Has Proposed Coverage With Evidence Development For CAR-T Therapy, Decision Would Provide Nationwide Consistency In CMS Coverage

Financial news for CLVS dated on 2019-02-13: Benzinga's Top Upgrades, Downgrades For February 13, 2019

Financial news for CLVS dated on 2019-02-13: H.C. Wainwright Initiates Coverage On Clovis Oncology with Buy Rating, Announces \$40 Price Target

Financial news for CLVS dated on 2019-02-11: Clovis Oncology Option Alert: Fri \$25 Calls at the Ask: 500 @ \$0.85 vs 1566 OI; Earnings 2/25 After Close [est] Ref=\$24.62

Financial news for CLVS dated on 2019-02-06: Clovis Oncology Option Alert: Apr 18 \$30 Calls at the Bid: 1000 @ \$2.65 vs 3383 OI; Earnings 2/25 After Close [est] Ref=\$26.01

Financial news for CLVS dated on 2019-01-24: Clovis Oncology Reports Rucaparib Is Now Available To Patients Regardless Of Their BRCA Mutation Status

Financial news for CLVS dated on 2019-01-23: 'Clovis Oncology receives European Commission approval of Rubraca as a maintenance treatment for women with relapsed ovarian cancer.' -TradeHawk Tweets, Citing Screenshot Of Document

Financial news for CLVS dated on 2019-01-18: Clovis Oncology Option Alert: Fri \$22.5 Calls Sweep (7) near the Ask: 888 @ \$1.598 vs 6370 OI; Earnings 2/25 After Close [est] Ref=\$23.91

Financial news for CLVS dated on 2019-01-09: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2019-01-08: 65 Biggest Movers From Yesterday

Financial news for CLVS dated on 2019-01-07: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for CLVS dated on 2019-01-07: Shares of several cancer therapeutics companies are trading higher after Loxo Oncology received an acquisition offer from Eli Lilly.

Financial news for CLVS dated on 2019-01-07: Clovis Oncology Sees Rubraca Q4 Sales \$30.3M to \$30.8M

Financial news for CLVS dated on 2018-12-17: Activist To Push Clovis To Explore A Sale

Financial news for CLVS dated on 2018-12-14: 26 Stocks Moving In Friday's Mid-Day Session

Financial news for CLVS dated on 2018-12-13: Clovis Oncology Option Alert: Dec 21 \$22 Calls Sweep (2) near the Ask: 500 @ \$1.351 vs 477 OI; Ref=\$21.28

Financial news for CLVS dated on 2018-12-13: Shares of Clovis Oncology trading higher after the CHMP granted a positive opinion for a new indication of the company's Rubraca tablets for ovarian cancer.

Financial news for CLVS dated on 2018-12-13: CHMP Grants Positive Opinion For New Indication Of Clovis Oncology's Rubraca Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer

Financial news for CLVS dated on 2018-12-11: Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

Financial news for CLVS dated on 2018-12-11: UPDATE: Gabelli On Clovis Says Continues 'to believe Bristol, Sanofi and Roche to be the most interested buyers'

Financial news for CLVS dated on 2018-12-11: Clovis Oncology Shares Up 3.8%; Gabelli Issued Earlier Note Highlighting Stock As The Top Biotech Pick For 2019 Given Tesaro Acquisition, 'CLVS will become the only standalone PARP, which we believe makes it the most likely takeout target in 2019'

Financial news for CLVS dated on 2018-12-06: 50 Biggest Movers From Tuesday

Financial news for CLVS dated on 2018-12-04: 40 Stocks Moving In Tuesday's Mid-Day

## Session

Financial news for CLVS dated on 2018-12-04: Clovis Oncology shares are trading higher after the European Patent Office upheld patent claims to protect its Rubraca Crystalline.

Financial news for CLVS dated on 2018-12-04: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLVS dated on 2018-12-04: Clovis Oncology Reports European Patent Office Upheld Patent Claims Directed To Rubraca Crystalline

Financial news for CLVS dated on 2018-12-04: 56 Biggest Movers From Yesterday

Financial news for CLVS dated on 2018-12-03: 46 Stocks Moving In Monday's Mid-Day Session

Financial news for CLVS dated on 2018-12-03: Benzinga Pro's Top 10 Most-Searchd Tickers For Afternoon Of Mon., Dec. 3, 2018

Financial news for CLVS dated on 2018-12-03: Clovis Oncology shares are trading high in sympathy with the 60% acquisition premium paid for TESARO.

Financial news for CLVS dated on 2018-12-03: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2018-12-03: Clovis Oncology Shares Up 32% Premarket, Likely Trading Higher In Sympathy With 60% Upside Move In Tesaro Following \$6B Deal For Glaxo To Buy Tesaro

Financial news for CLVS dated on 2018-11-20: Clovis Oncology Reports Second US Patent Issued In Rucaparib High Dosage Strength Tablet Patent Family With Expiration In 2035

Financial news for CLVS dated on 2018-11-07: 75 Biggest Movers From Yesterday

Financial news for CLVS dated on 2018-11-06: 60 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLVS dated on 2018-11-06: Armistice Capital Earlier Showed a 9.8% Stake in Clovis Oncology in a 13D Filing

Financial news for CLVS dated on 2018-11-02: 76 Biggest Movers From Yesterday

Financial news for CLVS dated on 2018-11-01: Stocks Which Set New 52-Week Low Yesterday, October 31st

Financial news for CLVS dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for CLVS dated on 2018-11-01: 82 Biggest Movers From Yesterday

Financial news for CLVS dated on 2018-10-31: 66 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLVS dated on 2018-10-31: 8 Biggest Price Target Changes For Wednesday

Financial news for CLVS dated on 2018-10-31: 38 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for CLVS dated on 2018-10-31: JP Morgan Downgrades Clovis Oncology to Neutral, Lowers Price Target to \$16

Financial news for CLVS dated on 2018-10-30: Clovis Oncology shares are down 23.2% after the company missed Q3 EPS and sales estimates.

Financial news for CLVS dated on 2018-10-30: Clovis Oncology Sees Q4 Sales Unchanged Or Slightly Higher Than Q3'18 Sales

Financial news for CLVS dated on 2018-10-30: Clovis Oncology Q3 EPS \$(1.71) Misses \$(1.64) Estimate, Sales \$22.757M Miss \$30.01M Estimate

Financial news for CLVS dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for CLVS dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And

Allergan Earnings, CFO Departures At Acadia And Assertio

Financial news for CLVS dated on 2018-10-29: Clovis Oncology 8-K Shows Senior Vice President And Chief Commercial Officer Cowrin Dale Hooks Has Left Company

Financial news for CLVS dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for CLVS dated on 2018-10-25: Clovis Oncology 13G From Camber Capital Management Shows Raised Stake In Co. From 1M Shares To 3.5M Shares

Financial news for CLVS dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for CLVS dated on 2018-10-24: Stocks Which Set New 52-Week Low Yesterday, October 23rd

Financial news for CLVS dated on 2018-10-24: The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering

Financial news for CLVS dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for CLVS dated on 2018-10-23: The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Financial news for CLVS dated on 2018-10-23: 58 Biggest Movers From Yesterday

Financial news for CLVS dated on 2018-10-22: 45 Stocks Moving In Monday's Mid-Day Session

Financial news for CLVS dated on 2018-10-22: 58 Biggest Movers From Friday

Financial news for CLVS dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for CLVS dated on 2018-10-19: '\$CLVS -4%. Why? Rubraca prostate cancer data released today at #ESMO18 are fine, perhaps even better than expected, but ovarian competition is a big overhang to overcome.' -STAT News' Adam Feuerstein Tweets

Financial news for CLVS dated on 2018-10-19: Clovis Oncology shares are trading higher after the company's Rubraca study showed positive results.

Financial news for CLVS dated on 2018-10-19: Clovis Oncology Presents Initial Results from the Ongoing Rubraca(r) (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer at ESMO 2018

Financial news for CLVS dated on 2018-10-12: Stocks Which Set New 52-Week Low Yesterday, October 11th

Financial news for CLVS dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for CLVS dated on 2018-10-11: Stocks Which Set New 52-Week Low Yesterday, October 10th

Financial news for CLVS dated on 2018-10-11: The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares

Financial news for CLVS dated on 2018-10-10: Stocks Which Set New 52-Week Low Yesterday, October 9th

Financial news for CLVS dated on 2018-10-03: 45 Biggest Movers From Yesterday

Financial news for CLVS dated on 2018-10-02: Mid-Afternoon Market Update: Stitch Fix Falls After Q4 Results; Pyxus International Shares Climb

Financial news for CLVS dated on 2018-10-02: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLVS dated on 2018-10-02: Clovis Oncology Receives Breakthrough Therapy Designation From FDA For Its Rubraca (rucaparib) For Treatment Of BRCA1/2-Mutated Metastatic Castration Resistant Prostate Cancer

Financial news for CLVS dated on 2018-09-28: The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results



Financial news for CLVS dated on 2018-09-26: Stocks Which Set New 52-Week Low Yesterday, September 25th

Financial news for CLVS dated on 2018-09-25: Leerink Swann Initiates Coverage On Clovis Oncology with Market Perform Rating, Announces \$30 Price Target

Financial news for CLVS dated on 2018-09-18: Clovis Oncology CEO And Former CFO To Pay More Than \$20M In Penalties, SEC Says Co. Misled Investors About Its Cancer Drug

Financial news for CLVS dated on 2018-09-14: Stocks Which Set New 52-Week Low Yesterday, September 13th

Financial news for CLVS dated on 2018-09-13: Stocks Which Set New 52-Week Low Yesterday, September 12th

Financial news for CLVS dated on 2018-09-13: The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

Financial news for CLVS dated on 2018-09-12: Stocks Which Set New 52-Week Low Yesterday, September 11th

Financial news for CLVS dated on 2018-08-09: Stocks Which Set New 52-Week Low Yesterday, August 8th

Financial news for CLVS dated on 2018-08-09: The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Financial news for CLVS dated on 2018-08-08: Stocks Which Set New 52-Week Low Yesterday, August 7th

Financial news for CLVS dated on 2018-08-07: Stocks Which Set New 52-Week Low Yesterday, August 6th

Financial news for CLVS dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmmed's Antibiotic Faces FDA Panel

Financial news for CLVS dated on 2018-08-06: Stocks Which Set New 52-Week Lows Friday, August 3rd

Financial news for CLVS dated on 2018-08-06: 66 Biggest Movers From Friday

Financial news for CLVS dated on 2018-08-03: 56 Stocks Moving In Friday's Mid-Day Session

Financial news for CLVS dated on 2018-08-03: Stocks Which Set New 52-Week Low Yesterday, August 2nd

Financial news for CLVS dated on 2018-08-03: The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

Financial news for CLVS dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for CLVS dated on 2018-08-01: Clovis Oncology Q2 Adj. EPS \$(1.55) Beats \$(1.88) Estimate, Sales \$23.8M Beat \$22.44M Estimate

Financial news for CLVS dated on 2018-08-01: Clovis Oncology Option Alert: Oct 19 \$55 Calls at the Bid: 1612 @ \$3.0 vs 344 OI; Earnings 8/1 After Close Ref=\$45.73

Financial news for CLVS dated on 2018-08-01: Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

Financial news for CLVS dated on 2018-07-30: Clovis Oncology Option Alert: Sep 21 \$60 Calls at the Ask: 500 @ \$0.551 vs 144 OI; Earnings 8/1 After Close Ref=\$43.36

Financial news for CLVS dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for CLVS dated on 2018-07-05: Clovis Oncology Receives EMA Validation for its Application for a New Indication for Rubraca, Says Timing Of Validation By EMA May Allow For CHMP Opinion On Maintenance Treatment By Year-End 2018

Financial news for CLVS dated on 2018-06-22: Clovis Oncology Option Alert: Jul 20 \$50 Calls at the Ask: 1075 @ \$2.25 vs 5441 OI; Earnings 8/1 After Close [est] Ref=\$48.11

Financial news for CLVS dated on 2018-06-04: Clovis Oncology Submits an Application to the EMA to Expand Use of Rubraca

Financial news for CLVS dated on 2018-06-03: Clovis Oncology, Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers

Financial news for CLVS dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for CLVS dated on 2018-05-30: Jim Cramer Advises His Viewers On Groupon, Adobe And More

Financial news for CLVS dated on 2018-05-29: Clovis Oncology Announces European Commission Authorization of Rubraca for Women with Recurrent Ovarian Cancer

Financial news for CLVS dated on 2018-05-09: Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Financial news for CLVS dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for CLVS dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for CLVS dated on 2018-05-01: Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

Financial news for CLVS dated on 2018-04-26: Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings

Financial news for CLVS dated on 2018-04-17: 38 Biggest Movers From Yesterday

Financial news for CLVS dated on 2018-04-17: Clovis Oncology Prices ~1.84M Share Offering @\$54.41/Share

Financial news for CLVS dated on 2018-04-16: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for CLVS dated on 2018-04-16: 23 Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2018-04-10: In An 8-K Filing, Clovis Oncology Reported SEC Receipt Of 'Wells Notices' On April 9th

Financial news for CLVS dated on 2018-04-06: Clovis Announces FDA Approval For Rucaparib

Financial news for CLVS dated on 2018-04-06: REMINDER: Clovis Has FDA PDUFA Date For Rucaparib sNDA Today

Financial news for CLVS dated on 2018-04-03: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for CLVS dated on 2018-04-02: The Week Ahead: Switch's Lockup Expires, Spotify Debuts, And More

Financial news for CLVS dated on 2018-03-30: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences

Financial news for CLVS dated on 2018-03-28: For Now, Traders Endorse Biotech Rally

Financial news for CLVS dated on 2018-03-23: CHMP Grants Positive Opinion for Clovis Oncology's Rubraca Tablets

Financial news for CLVS dated on 2018-03-23: Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe

Financial news for CLVS dated on 2018-03-23: Clovis Oncology Reports Initiation Of Early Access Program For Rucaparib As Treatment, Maintenance Therapy In Recurrent Ovarian Cancer In Europe

Financial news for CLVS dated on 2018-03-23: Clovis Oncology Reports CHMP Recommended Granting Of Conditional Marketing Authorization For Rubraca As Monotherapy Treatment Of Adult Patients With Cancer

Financial news for CLVS dated on 2018-03-08: Clovis Oncology Reports Notice Of Allowance For Rucaparib High-Dosage Strength Tablet Patent

Financial news for CLVS dated on 2018-02-27: Mid-Afternoon Market Update: Crude Oil Down 1.5%; Mallinckrodt Shares Climb After Strong Q4 Results

Financial news for CLVS dated on 2018-02-27: Mid-Day Market Update: U.S. Stocks Turn Lower; Dillard's Shares Gain On Earnings Beat

Financial news for CLVS dated on 2018-02-27: Stifel Nicolaus Maintains Buy on Clovis Oncology, Lowers Price Target to \$110.00

Financial news for CLVS dated on 2018-02-26: Clovis Oncology Reports Q4 Adj. EPS \$(1.27) vs \$(1.30) Est., Sales \$17.04M vs \$20.1M Est.

Financial news for CLVS dated on 2018-02-25: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for CLVS dated on 2018-02-23: 56 Biggest Movers From Yesterday

Financial news for CLVS dated on 2018-02-22: 45 Stocks Moving In Thursday's Mid-Day Session

Financial news for CLVS dated on 2018-02-22: Benzinga's Top Upgrades, Downgrades For February 22, 2018

Financial news for CLVS dated on 2018-02-22: The Market In 5 Minutes: Jobless Claims Fall, 10-Year Treasury Yields, Twitter Makes Some Changes

Financial news for CLVS dated on 2018-02-22: Evercore ISI Group Upgrades Clovis Oncology to Outperform

Financial news for CLVS dated on 2018-02-22: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for CLVS dated on 2018-02-22: RBC Capital Upgrades Clovis Oncology to Outperform

Financial news for CLVS dated on 2018-02-21: Clovis Oncology Reports CHMP Has Communicated A Positive Trend Vote For Rucaparib MAA Under Review

Financial news for CLVS dated on 2018-02-20: Clovis Shares Up 2.55%, Traders Attributing Strength To Chatroom Rumor Of M&A Interest

Financial news for CLVS dated on 2017-12-19: Clovis Oncology Reports Rucaparib MAA As Treatment For Ovarian Cancer Referred By CHMP To Scientific Advisory Group On Oncology For Review Expected In Feb. '18

Financial news for CLVS dated on 2017-12-08: Clovis Shars Pop To High Of \$60.44/Share Up 1.2% On Day

Financial news for CLVS dated on 2017-12-05: Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application

Financial news for CLVS dated on 2017-11-15: Stifel 2017 Healthcare Conference Concludes Today, Presenters Include: Eleven Biotherapeutics, Clovis, Puma Biotechnology, Synlogic, KalVista Pharmaceuticals, Dicerna Pharmaceuticals, GTx, and Acorda Therapeutics

Financial news for CLVS dated on 2017-11-08: Credit Suisse Adjusts Its Top Picks List In A Record-Breaking Market

Financial news for CLVS dated on 2017-11-01: Clovis Oncology Reports Q3 Adj. EPS \$(1.24) vs \$(1.22) Est., Sales \$16.806M vs \$21.12M Est.

Financial news for CLVS dated on 2017-10-23: Benzinga's Top Upgrades, Downgrades For October 23, 2017

Financial news for CLVS dated on 2017-10-23: Barclays Initiates Coverage On Clovis Oncology with Overweight Rating, Announces \$105.00 Price Target

Financial news for CLVS dated on 2017-10-10: 5 Stocks To Watch For October 10, 2017

Financial news for CLVS dated on 2017-10-09: 16 Stocks Moving In Monday's After-Hours Session

Financial news for CLVS dated on 2017-10-09: Clovis Oncology Submits sNDA For Rucaparib

Financial news for CLVS dated on 2017-09-27: Clovis Shares Up 6.5% Wed. Following 4.7% Decline Over Tues.; Not Seeing Any Formal News To Justify Price Action But Stock Has Been Mentioned By The Rumor Mill At Least Twice Over 2017, Most Recently On Sept. 18

Financial news for CLVS dated on 2017-09-19: Wall Street's M&A Chatter From September 18: Walgreens-Rite Aid, Northrup Grumman-Orbital ATK, Itron-Silver Spring Networks

Financial news for CLVS dated on 2017-09-18: Clovis Oncology Higher Off Unconfirmed Takeover Chatter

Financial news for CLVS dated on 2017-09-18: UPDATE: Clovis Spokesperson Says Co. 'remains focused on bringing Rubraca (rucaparib) to women with ovarian cancer and, eventually, to patients with other solid tumors that may be addressed by PARP inhibitors'

Financial news for CLVS dated on 2017-09-18: Clovis Oncology Spokesperson Declines Comment Following Chatroom Chatter Of Takeover Interest

Financial news for CLVS dated on 2017-09-18: Clovis Oncology Shares Now Up 6% Following Chatroom Chatter

Financial news for CLVS dated on 2017-09-18: Clovis Shares Spike ~\$2 As Traders Circulate Takeover Chatter Via Chatroom

Financial news for CLVS dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for CLVS dated on 2017-09-14: RBC Initiates Coverage on 6 Pharma Stocks After Hours

Financial news for CLVS dated on 2017-09-13: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2017-09-13: A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Producer Price, Treasury Budget Data

Financial news for CLVS dated on 2017-09-13: Clovis Oncology's Rucaparib ARIEL3 Study Met Primary, Secondary Endpoints

Financial news for CLVS dated on 2017-09-08: European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5

Financial news for CLVS dated on 2017-09-08: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for CLVS dated on 2017-09-07: Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017

Financial news for CLVS dated on 2017-08-17: Evercore ISI Group Initiates Coverage On Clovis Oncology with In-Line Rating, Announces \$73.00 Price Target

Financial news for CLVS dated on 2017-08-14: 13F From Omega Shows Small, New Stakes In Bluebird Bio and Clovis Oncology

Financial news for CLVS dated on 2017-08-08: A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision

Financial news for CLVS dated on 2017-08-02: Clovis Oncology Reports Q2 EPS \$(3.88) vs \$(2.13) Est., Sales \$14.62M vs \$13.31M Est.

Financial news for CLVS dated on 2017-07-31: 15 Biggest Mid-Day Losers For Monday

Financial news for CLVS dated on 2017-07-31: Hearing JP Morgan Is Reiterating Their Overweight Rating; Says Clovis Takeover Is Not Off The Table Following Earlier News Of Partnership With Bristol-Myers, Explains That This Is A 'No-Strings'Attached' Clinical Collaboration

Financial news for CLVS dated on 2017-07-31: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2017-07-31: Bristol-Myers and Clovis Oncology to Collaborate on Opdivo and Rubraca In Phase 2 and Phase 3 Trials

Financial news for CLVS dated on 2017-07-07: Clovis Shares Now Up 3.38% At \$96.03/Share

Financial news for CLVS dated on 2017-07-07: Clovis Oncology Shares Spiking Higher, Gabelli & Co. Initiated On Company Earlier This Morning With A Buy And \$125 Price Target

Financial news for CLVS dated on 2017-06-23: What To Expect From Clovis Oncology Following Rubraca Approval

Financial news for CLVS dated on 2017-06-23: 12 Biggest Mid-Day Losers For Friday

Financial news for CLVS dated on 2017-06-23: Benzinga's Top Upgrades, Downgrades For June 23, 2017

Financial news for CLVS dated on 2017-06-23: Oppenheimer Initiates Coverage On Clovis Oncology with Market Perform Rating

Financial news for CLVS dated on 2017-06-21: Clovis Oncology Prices Upsized ~3.409M Share Offering @\$88.00/Share

Financial news for CLVS dated on 2017-06-20: Clovis Addresses Some Of The Company's Biggest Controversies

Financial news for CLVS dated on 2017-06-20: 10 Biggest Mid-Day Gainers For Tuesday

Financial news for CLVS dated on 2017-06-20: 5 Biggest Price Target Changes For Tuesday

Financial news for CLVS dated on 2017-06-20: Benzinga's Top Upgrades, Downgrades For June 20, 2017

Financial news for CLVS dated on 2017-06-20: Adam Feuerstein Tweets: I wrote about \$CLVS potential takeout in The Readout this a.m. Subscribe, it's free, delivered to your inbox! [statnews.com/signup/readout](http://statnews.com/signup/readout)

Financial news for CLVS dated on 2017-06-20: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLVS dated on 2017-06-20: A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Fed Speakers

Financial news for CLVS dated on 2017-06-20: Janney Capital Upgrades Clovis Oncology to Buy

Financial news for CLVS dated on 2017-06-20: 7 Stocks To Watch For June 20, 2017

Financial news for CLVS dated on 2017-06-19: Clovis Announces \$250M Offering Common Stock

Financial news for CLVS dated on 2017-06-19: Mid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher

Financial news for CLVS dated on 2017-06-19: 15 Biggest Mid-Day Gainers For Monday

Financial news for CLVS dated on 2017-06-19: Mid-Day Market Update: Dow Gains 100 Points; Performant Financial Shares Tumble

Financial news for CLVS dated on 2017-06-19: Tesaro Comes Roaring Back From Much Lower Open

Financial news for CLVS dated on 2017-06-19: Mid-Morning Market Update: Markets Open Higher; EQT To Buy Rice Energy For \$6.7B

Financial news for CLVS dated on 2017-06-19: Benzinga's Top Upgrades, Downgrades For June 19, 2017

Financial news for CLVS dated on 2017-06-19: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for CLVS dated on 2017-06-19: Clovis Oncology's 45% Pre-Market Surge, Explained

Financial news for CLVS dated on 2017-06-19: Chardan Capital Upgrades Clovis Oncology to Neutral

Financial news for CLVS dated on 2017-06-19: Clovis Oncology Announces \$142M Class Action Settlement -8K

Financial news for CLVS dated on 2017-06-19: Clovis Oncology Announces Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial; Plans to Submit sNDA

Financial news for CLVS dated on 2017-06-13: Benzinga's Top Upgrades, Downgrades For June 13, 2017

Financial news for CLVS dated on 2017-06-13: Leerink Swann Initiates Coverage On

Clovis Oncology with Outperform Rating, Announces \$85.00 Price Target

Financial news for CLVS dated on 2017-06-08: Companies Holding Shareholder Meetings Today Include: Aerie Pharma, Agile Therapeutics, bluebird bio, Bojangles, Comcast, Clovis Oncology, Etsy, Egalet, Dave And Busters, Ingersoll-Rand, Priceline, Lululemon, Rent-A-Center, Splunk, & Zoe's Kitchen

Financial news for CLVS dated on 2017-05-31: Adam Feuerstein Tweets '\$TSRO "for sale" news good reminder: Plenty 'o PARP data coming. \$AZN OlympiAD breast at #ASCO17 (plenary) \$CLVS ARIEL-3 end of June'

Financial news for CLVS dated on 2017-05-31: Tesaro, Clovis Shares Spike Higher Amid Report Tesaro is Exploring Sale, Has Asked for Initial Bids in Recent Weeks

Financial news for CLVS dated on 2017-05-17: Benzinga's Top Upgrades, Downgrades For May 17, 2017

Financial news for CLVS dated on 2017-05-17: The Market In 5 Minutes

Financial news for CLVS dated on 2017-05-17: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2017-05-17: JP Morgan Upgrades Clovis Oncology to Overweight

Financial news for CLVS dated on 2017-05-04: Adam Feuerstein Tweets: Biotech Stock Mailbag: Why \$CLVS is Trading Lower on Rubraca Study Update --> thestreet.com/story/14119676... The PARP wars! \$TSRO \$AZN

Financial news for CLVS dated on 2017-05-03: Clovis Oncology Reports Q1 EPS \$(1.33) vs \$(1.48) Est., Sales \$7.045M May Not Compare \$4.89M Est.

Financial news for CLVS dated on 2017-05-02: Benzinga's Option Alert Recap From May 2

Financial news for CLVS dated on 2017-05-02: Option Alert: Clovis May 65.0 Calls: 1100 @ ASK \$1.60: 1584 traded vs 3367 OI: Earnings tmrrw After Close \$57.63 Ref

Financial news for CLVS dated on 2017-04-27: Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space

Financial news for CLVS dated on 2017-04-27: Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRCAAnalysis CDx Test to Identify Patients with Germline BRCA Mutations for Rubraca

Financial news for CLVS dated on 2017-03-28: Tesaro Gets Approval For Zejula, Expect U.S. Launch Late April

Financial news for CLVS dated on 2017-03-27: Tesaro Announces Expanded Development Program For Cancer Drug Niraparib, Stock Spikes Higher

Financial news for CLVS dated on 2017-03-27: Clovis Shares Selling Off On TESARO Approval Of niraparib

Financial news for CLVS dated on 2017-03-27: Clovis Spikes to High of \$70.30

Financial news for CLVS dated on 2017-03-20: Leerink Presents: Your 2017 Biopharma Catalyst Tracker

Financial news for CLVS dated on 2017-03-15: Lynparza Vs. Niraparib

Financial news for CLVS dated on 2017-03-15: Clovis Shares Reiterated As A Sell Following 10% Rally

Financial news for CLVS dated on 2017-03-14: Clovis Spikes to High of \$65.78 on Volume Following Lynparza Results

Financial news for CLVS dated on 2017-03-14: Adam Feuerstein Tweets: \$AZN Takes PARP Inhibitor Fight to Rival \$TSRO with Strong Ovarian Cancer Study Results --> thestreet.com/story/14043007... \$CLVS, too.

Financial news for CLVS dated on 2017-03-14: Adam Feuerstein Tweet \$AZN Lynparza SOLO-2 ovarian cancer maintenance therapy data in 10 minutes. Watch \$TSRO \$CLVS for reaction, as well. Battle of the PARPs.

Financial news for CLVS dated on 2017-03-13: Wall Street's M&A Chatter From March 10-12

Financial news for CLVS dated on 2017-03-12: Clovis Announces Presentation of New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual

## Meeting on Women's Cancer

Financial news for CLVS dated on 2017-02-24: Clovis Says, In Their Recent 10-K, They Believe Macalinalao Demand Letter To Investigate Alleged Misconduct Relating To rociletinib Is Unfounded And Fails To Establish An Entitlement To Any Of The Requested Documents

Financial news for CLVS dated on 2017-02-22: Clovis Oncology Reports Q4 Adj. EPS \$(1.83) vs. \$(1.65) Est.

Financial news for CLVS dated on 2017-02-22: venBio Says It's Committed TO Delivering Much-Needed Change At Immunomedics In Shareholder Letter

Financial news for CLVS dated on 2017-02-17: Benzinga's Option Alert Recap From February 17

Financial news for CLVS dated on 2017-02-17: Option Alert: Clovis Feb \$65 Call; 2983 @Bid @\$0.35

Financial news for CLVS dated on 2017-02-10: venBio Comments on Immunomedics Partnership Announcement, Says Co. Blatantly Spurning Will Of Stockholders

Financial news for CLVS dated on 2017-02-09: State Street Reports 5.55% Passive Stake in Clovis Oncology in 13G

Financial news for CLVS dated on 2017-02-06: Clovis Oncology Sells off to Low of \$61.10 on Volume

Financial news for CLVS dated on 2017-02-03: 18 Biggest Mid-Day Losers For Friday

Financial news for CLVS dated on 2017-02-03: Benzinga's Top Upgrades, Downgrades For February 3, 2017

Financial news for CLVS dated on 2017-02-03: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for CLVS dated on 2017-02-03: Chardan Capital Downgrades Clovis Oncology To Sell, Announces \$36 Price Target

Financial news for CLVS dated on 2017-02-01: Clovis Oncology, Strata Oncology Partner to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program

Financial news for CLVS dated on 2017-01-27: Benzinga's Top Upgrades, Downgrades For January 27, 2017

Financial news for CLVS dated on 2017-01-27: Bank of America Initiates Coverage On Clovis Oncology At Buy

Financial news for CLVS dated on 2017-01-26: Benzinga's Top Upgrades, Downgrades For January 26, 2017

Financial news for CLVS dated on 2017-01-26: PiperJaffray Upgrades Clovis Oncology To Overweight

Financial news for CLVS dated on 2017-01-25: Which Pharma Players Dominate The Lung Cancer Space?

Financial news for CLVS dated on 2017-01-17: Here's What To Expect Following Trump's Drug Pricing 'Robbery' Comments

Financial news for CLVS dated on 2017-01-13: Clovis Oncology Shares Up ~6% Friday Following Earlier New Overweight Rating from Morgan Stanley

Financial news for CLVS dated on 2017-01-12: Clovis Shares Continue Recent Run Thurs., Up ~10%; Stock Up 22+% YTD, Up Nearly 90% Since Beginning of Nov.; Earlier 13G Filing from Integrated Core Strategies Showed New 5.1% Stake

Financial news for CLVS dated on 2017-01-04: Clovis Oncology Announces Prices Upsized 5M Share Offering @\$41.00/Share

Financial news for CLVS dated on 2017-01-03: Hearing Clovis Oncology Offering Upsized and Expected to Price Around \$41

Financial news for CLVS dated on 2017-01-03: A Peek Into The Markets: U.S. Stock Futures Surge On First Trading Day Of 2017

Financial news for CLVS dated on 2017-01-03: Clovis Oncology Announces \$175M Offering

Financial news for CLVS dated on 2016-12-27: Expect Availability Of Biogen's Newly

Approved Spinraza In Just One Week

Financial news for CLVS dated on 2016-12-23: 6 Best Biotech Stocks Of 2016

Financial news for CLVS dated on 2016-12-21: 4 Stocks With Technical Momentum

Financial news for CLVS dated on 2016-12-21: Breaking Down The Crowded Novel Ovarian Cancer Treatment Space

Financial news for CLVS dated on 2016-12-20: Clovis' Rubraca Vs. TESARO's Niraparib

Financial news for CLVS dated on 2016-12-20: Benzinga's Top Upgrades, Downgrades For December 20, 2016

Financial news for CLVS dated on 2016-12-20: Chardan Capital Upgrades Clovis Oncology to Neutral, Announces \$36.00 Target

Financial news for CLVS dated on 2016-12-19: Credit Suisse Says Clovis Oncology's Rubraca Accelerated Approval Comes With Best-Case Scenario Label, Increases Price Target From \$41 To \$50, Continues To See Clovis As Potential Takeout Target

Financial news for CLVS dated on 2016-12-19: Mid-Afternoon Market Update: Dow Gains Over 50 Points; Globalstar Shares Surge Following FCC News

Financial news for CLVS dated on 2016-12-19: Unexpected FDA Approval May Spark Extended Clovis Short Squeeze

Financial news for CLVS dated on 2016-12-19: Clovis Oncology Opens, Spikes To \$46.97, Now at \$45

Financial news for CLVS dated on 2016-12-19: Adam Feuerstein Tweets '\$CLVS Rubraca approval has little bearing on \$TSRO given different ovarian cancer pat pops. Rubraca more competes w/ \$AZN Lynparza.'

Financial news for CLVS dated on 2016-12-19: Clovis Oncology To Resume At 1:20pm ET

Financial news for CLVS dated on 2016-12-19: PR Confirms Clovis Oncology Receives FDA Accelerated Approval of RUBRACA

Financial news for CLVS dated on 2016-12-19: FDA Approves Clovis Oncology's Ovarian Cancer Treatment

Financial news for CLVS dated on 2016-12-19: Code on Clovis Shares Switched from Circuit Breaker to News Pending

Financial news for CLVS dated on 2016-12-19: Clovis Shares to Resume Trade at 11:15:59 a.m. EST

Financial news for CLVS dated on 2016-12-19: TESARO Shares Spike ~\$3 Lower Following News Out on Clovis' Rubraca

Financial news for CLVS dated on 2016-12-19: Adam Feuerstein Tweets: \$CLVS - FDA approves rucaparib for ovarian cancer. Brand name: Rubraca

Financial news for CLVS dated on 2016-12-19: Clovis Oncology Shares Spiking To \$42 Level

Financial news for CLVS dated on 2016-12-08: 10 Stocks That Rallied Four Days, Then Sold Off Yesterday

Financial news for CLVS dated on 2016-11-29: Clovis Oncology Up 4.6% On Yesterday's Publication Of rucaparib Data In The Lancet Oncology

Financial news for CLVS dated on 2016-11-23: Vetr Crowd Doesn't Like Outlook For Clovis Oncology

Financial news for CLVS dated on 2016-11-23: Can You Guess This Chart?

Financial news for CLVS dated on 2016-11-14: Clovis Spikes to High of \$35.41 on Volume

Financial news for CLVS dated on 2016-11-03: Clovis Oncology Reports Q3 EPS \$(1.70) vs. Est. \$(1.95)

Financial news for CLVS dated on 2016-10-25: Benzinga's Top Initiations

Financial news for CLVS dated on 2016-10-25: The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind



Financial news for CLVS dated on 2016-10-25: Chardan Recommends Selling Clovis Oncology

Financial news for CLVS dated on 2016-10-25: Chardan Capital Initiates Coverage On Clovis Oncology, Inc. - Common Stock at Sell, Announces \$15.00

Financial news for CLVS dated on 2016-10-18: Watch These 7 Huge Call Purchases In Tuesday Trade

Financial news for CLVS dated on 2016-10-17: Option Alert: CLVS Oct16 30.0 Calls: 2400 @ Above Ask! \$2.60: 2560 traded vs 4906 OI: Earnings 11/3 \$31.96 Ref

Financial news for CLVS dated on 2016-10-17: 5 Stocks Which Rallied Four Days, Then Sold Off On Friday

Financial news for CLVS dated on 2016-10-14: 12 Stocks Which Rallied For Three Days

Financial news for CLVS dated on 2016-10-13: 15 Stocks That Rallied For Three Days On No News

Financial news for CLVS dated on 2016-10-07: Mid-Afternoon Market Update: Crude Oil Down 1.3%; Ruby Tuesday Shares Fall Following Q1 Results

Financial news for CLVS dated on 2016-10-07: 18 Biggest Mid-Day Losers For Friday

Financial news for CLVS dated on 2016-10-07: Mid-Day Market Update: Dow Drops Over 100 Points; Gap Shares Rise Following September Sales Numbers

Financial news for CLVS dated on 2016-10-07: Hearing SunTrust Analyst Issues Defense on Clovis, Highlighting 'Nothing Significantly New in Data'

Financial news for CLVS dated on 2016-10-07: Adam Feuerstein @adamfeuerstein Tweet: \$CLVS falls on fears ovarian cancer drug inferior to competition thestreet.com/story/13845913... Worry not ruca approval but comp. to \$AZN Lynparza

Financial news for CLVS dated on 2016-10-07: Mid-Morning Market Update: Markets Open Lower; Silicon Motion Raises Q3 Forecast

Financial news for CLVS dated on 2016-10-07: Clovis Oncology Tumbles 20% On Rucaparib Data

Financial news for CLVS dated on 2016-10-07: Incyte Trading Higher, Up 3.4% Pre-market At \$98/Share On Poor Clovis Data

Financial news for CLVS dated on 2016-10-07: UPDATE: 9 Patients In Clovis Study Had AEs That Led To Death, 8 From Disease Progression and 1 From Sepsis, Which Investigator Assessed Was Unrelated To Treatment

Financial news for CLVS dated on 2016-10-07: European Society For Medical Oncology Conference Commences Today (Oct.7 Thru Oct. 11)

Financial news for CLVS dated on 2016-10-05: BZ NOTE: Clovis Oncology Shares Up 16+% Over Last Couple Weeks Since Takeover Chatter in Name Was First Heard

Financial news for CLVS dated on 2016-10-05: Hearing Takeover Chatter In Clovis Oncology

Financial news for CLVS dated on 2016-10-04: UPDATE: Clovis Says Lonza Will Be Non-Exclusive Manufacturer of Rucaparib API Until Dec. 31, 2025

Financial news for CLVS dated on 2016-10-04: 8-K from Clovis Shows Co. Entered Long-Term Manufacture, Supply of Active Pharma Ingredient for Rucaparib

Financial news for CLVS dated on 2016-10-04: Abstracts Expected Wednesday From Companies Presenting At The European Society For Medical Oncology Conf. Beginning Oct. 7th, Including From Karyopharm Therapeutics, Kite Pharma And Clovis Oncology

Financial news for CLVS dated on 2016-09-21: Chasing Takeover Rumors Can Be Hazardous To Your Portfolio

Financial news for CLVS dated on 2016-09-21: Clovis Oncology Up 0.5% At \$35.12, Janney Lowering Clovis On Chance That Clovis Will Need To Market rucaparib itself; But Raising PT From \$30 To \$36 For Potential M&A

Financial news for CLVS dated on 2016-09-21: Hearing Clovis Oncology Downgraded To Neutral At Janney

Financial news for CLVS dated on 2016-09-21: Benzinga's Volume Movers

Financial news for CLVS dated on 2016-09-21: 7 Biggest Price Target Changes For Wednesday

Financial news for CLVS dated on 2016-09-21: More Pharma Deals In The Pipeline?

Financial news for CLVS dated on 2016-09-21: Benzinga's Top Upgrades

Financial news for CLVS dated on 2016-09-21: The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen

Financial news for CLVS dated on 2016-09-21: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2016-09-21: Clovis Upgraded At Credit Suisse Following Acquisition Rumor

Financial news for CLVS dated on 2016-09-21: Credit Suisse Upgrades Clovis Oncology to Outperform, Raises PT to \$41.00

Financial news for CLVS dated on 2016-09-20: After-Hours Gainers Sept. 20, 2016: CLVS Up 10.3%, ADMS 6.1%, SPSC 5.6%, ADBE 5%, FDX 2.7%, KBH 2.2%, MSFT 1%, SRPT 1%

Financial news for CLVS dated on 2016-09-20: Some Traders Attributing After-Hours Upside in Clovis to Janney Capital Analyst Comment During Bloomberg Interview There Are 'Many Suitors' for Co, Including Lilly, Roche, Merck

Financial news for CLVS dated on 2016-09-20: Clovis Oncology Shares Up Another 4% in Post-Market Action; Shares Closed Up 12.7% During Tuesday's Intraday Session

Financial news for CLVS dated on 2016-09-20: Clovis Spokesperson Responds to Rumor Of Potential Acquisition By Eli Lilly, Tells Benzinga Co. Policy Is to Not Comment On Rumors

Financial news for CLVS dated on 2016-09-20: Technical Alert: Rumor Mill Helps Clovis Oncology Near December Highs

Financial news for CLVS dated on 2016-09-20: Clovis Oncology Shares Now Up 10.3%; Off Session High of \$34.92

Financial news for CLVS dated on 2016-09-20: Traders Attributing Spike Higher in Clovis Oncology to Unconfirmed Chatter of Lilly Interest

Financial news for CLVS dated on 2016-09-20: Clovis Shares Spiking Higher

Financial news for CLVS dated on 2016-09-20: 18 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for CLVS dated on 2016-09-19: Mid-Afternoon Market Update: NASDAQ Turns Lower; Isle of Capri Casinos Shares Surge Following Merger News

Financial news for CLVS dated on 2016-09-16: 25 Stocks Which Rallied Three Days

Financial news for CLVS dated on 2016-09-15: 20 Stocks Which Rallied Three Days

Financial news for CLVS dated on 2016-09-08: Technical Alert: Clovis Oncology Nears \$30 For The First Time Since January

Financial news for CLVS dated on 2016-09-08: 15 Biggest Mid-Day Gainers For Thursday

Financial news for CLVS dated on 2016-09-08: Benzinga's Volume Movers

Financial news for CLVS dated on 2016-09-08: Option Alert: CLVS Sep16 25.0 Calls: 699 @ ASK \$2.80: 2658 traded vs 5119 OI: \$26.93 Ref

Financial news for CLVS dated on 2016-09-08: FDA Has Notified Clovis That FDA Is Not Currently Planning To Hold Advisory Committee Meeting To Discuss NDA For Rucaparib

Financial news for CLVS dated on 2016-09-02: 15 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for CLVS dated on 2016-08-24: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for CLVS dated on 2016-08-24: Technical Alert: Clovis Oncology Finds Resistance

Financial news for CLVS dated on 2016-08-24: Benzinga's Volume Movers

Financial news for CLVS dated on 2016-08-24: 14 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2016-08-23: UPDATE: Clovis Oncology Shares Now Up 34.5% Following FDA Acceptance of NDA for Priority Review of Rucaparib

Financial news for CLVS dated on 2016-08-23: Shares of Clovis Oncology Resume Trade, Continue Higher, Now Up 20%

Financial news for CLVS dated on 2016-08-23: Shares of Clovis Oncology to Resume Trade at 2:35:33 p.m. EDT

Financial news for CLVS dated on 2016-08-23: UPDATE: Clovis Says PDUFA Date of Feb. 23, 2017 Set

Financial news for CLVS dated on 2016-08-23: Clovis Shares Halted on Circuit Breaker, Swings Into Positive Territory, Now Up 4.6%

Financial news for CLVS dated on 2016-08-23: Clovis Oncology Reports FDA Accepted NDA for Rucaparib for Priority Review

Financial news for CLVS dated on 2016-08-09: Mid-Morning Market Update: Markets Open Higher; Coach Profit Beats Views

Financial news for CLVS dated on 2016-08-08: Clovis Oncology Reports Q2 Adj. EPS (2.07) vs. Est. \$(2.10)

Financial news for CLVS dated on 2016-08-08: Mid-Afternoon Market Update: Crude Oil Up 3.5%; Ceragon Shares Drop Following Q2 Results

Financial news for CLVS dated on 2016-08-05: The Market In 5 Minutes: Blowout Jobs Report Pushes Markets Higher

Financial news for CLVS dated on 2016-08-05: SunTrust Robinson Humphrey Initiates Coverage on Clovis Oncology at Buy

Financial news for CLVS dated on 2016-06-29: Clovis Higher In Sympathy With Tesaro

Financial news for CLVS dated on 2016-06-29: 12 Biggest Mid-Day Gainers For Wednesday

Financial news for CLVS dated on 2016-06-29: Benzinga's Volume Movers

Financial news for CLVS dated on 2016-06-29: Clovis Oncology Up 19.38% At \$14.70/Share In Sympathy To Tesaro

Financial news for CLVS dated on 2016-06-29: 13 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2016-06-27: Watch These 7 Huge Put Purchases In Monday Trade

Financial news for CLVS dated on 2016-06-24: Option Alert: CLVS Jul16 10.0 Puts: 3290 @ ASK \$0.40: 4326 traded vs 1127 OI: Earnings 8/4 \$13.01 Ref

Financial news for CLVS dated on 2016-06-16: 7 Stocks Moving In Thursday's After-Hours Session: Oracle, Smith & Wesson And More

Financial news for CLVS dated on 2016-06-10: 8 Biggest Mid-Day Losers For Friday

Financial news for CLVS dated on 2016-06-10: S-3 from Clovis Oncology Shows Registration for \$200M Mixed Securities Shelf Offering

Financial news for CLVS dated on 2016-06-06: Clovis Oncology Repost Phase 2 Rucaparib Data That Shows 38% Progression Recution

Financial news for CLVS dated on 2016-04-13: Mid-Afternoon Market Update: Dow Rises Over 1%; Medivation Shares Gain On Reported Pushback Of Sanofi Takeover Effort

Financial news for CLVS dated on 2016-04-13: Mid-Day Market Update: Repros Therapeutics Jumps Following Encouraging Study Results; Clovis Oncology Shares Drop

Financial news for CLVS dated on 2016-04-13: Clovis Investors Lose Roci Value Entirely, JPMorgan Sees Clovis Worth Just What Ruca Can Pay: \$15/Share

Financial news for CLVS dated on 2016-04-13: Mid-Morning Market Update: Markets Open Higher; JPMorgan Beats Q1 Expectations

Financial news for CLVS dated on 2016-04-13: Benzinga's Top Downgrades

Financial news for CLVS dated on 2016-04-13: 10 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLVS dated on 2016-04-13: UPDATE: JPMorgan Believes Best Way For Clovis To Unlock Value Would Be An Evaluation Of All Strategic Options For rucaparib To Extract Value

Financial news for CLVS dated on 2016-04-13: JPMorgan Reports \$15 Price Target On Clovis, Down From \$110 PT In November 2015; Says Risk/Reward Call Was Admittedly Low-Probability Event, Believed There Was Enough Value To Support Call; Admits It Did Not Work

Financial news for CLVS dated on 2016-04-13: JP Morgan Downgrades Clovis Oncology to Neutral, Lowers PT to \$15.00

Financial news for CLVS dated on 2016-04-12: Clovis Oncology Plummets After Rociletinib Approval Rejected

Financial news for CLVS dated on 2016-04-12: Clovis Shares Down ~20%

Financial news for CLVS dated on 2016-04-12: Clovis Shares Resume Trading, Opens Down Around \$12.70

Financial news for CLVS dated on 2016-04-12: Clovis Shares To Resume Trading At 2:20pm EST

Financial news for CLVS dated on 2016-04-12: Clovis Oncology Says They Are Disappointed With Today's Outcome, Believes In Strength Of rociletinib Data

Financial news for CLVS dated on 2016-04-12: Clovis Stock Trading Halted Ahead Of FDA Meeting

Financial news for CLVS dated on 2016-04-12: Clovis Oncology Shares Halted Ahead of FDA Panel Review of Rociletinib NDA for Treatment of Non-Small Cell Lung Cancer

Financial news for CLVS dated on 2016-04-11: Option Alert: CLVS Apr16 22.5 Calls: 500 @ Above Ask! \$0.76: 2410 traded vs 17k OI: Earnings 5/4 \$14.94 Ref

Financial news for CLVS dated on 2016-04-11: Stocks Hitting 52-Week Lows

Financial news for CLVS dated on 2016-04-08: Clovis Oncology Falls 8%: Here's What You Need To Know

Financial news for CLVS dated on 2016-04-08: Hearing Stifel Cautious on Clovis

Financial news for CLVS dated on 2016-04-08: Adam F/Street.com: Clovis Smart Move is to Drop Damaged Lung Cancer Drug Altogether

Financial news for CLVS dated on 2016-04-08: Clovis Oncology Reports FDA Posted Briefing Docs for Panel Meeting to Review Rociletinib

Financial news for CLVS dated on 2016-04-08: UPDATE: FDA Recommends Inclusion of Boxed Warning on Clovis' Drug

Financial news for CLVS dated on 2016-04-08: FDA Briefing Documents Out for Clovis' Lung Cancer Drug

Financial news for CLVS dated on 2016-04-04: Piper Jaffray Assumes Clovis Oncology at Neutral

Financial news for CLVS dated on 2016-03-29: Clovis Oncology Spikes to High of \$19.73 on Volume

Financial news for CLVS dated on 2016-03-02: Option Alert: CLVS Apr16 35.0 Calls Sweep: 663 @ ASK \$0.86: 7851 traded vs 341 OI: \$20.50 Ref

Financial news for CLVS dated on 2016-03-02: Option Alert: CLVS Apr16 22.5 Calls: 3000 @ Above Ask! \$4.00: 3245 traded vs 1015 OI: \$20.47 Ref

Financial news for CLVS dated on 2016-02-25: Clovis Oncology Reports Q4 EPS \$(2.23) Vs Est \$(2.44)

Financial news for CLVS dated on 2016-02-12: Clovis Oncology Issues Update On Rociletinib, Will Meet With FDA On April 12

Financial news for CLVS dated on 2016-02-12: Clovis Oncology Reports NDA For Rociletinib At Upcoming FDA Oncologic Drugs Advisory Committee Meeting

Financial news for CLVS dated on 2016-02-10: Goldman Sachs Reports 5.3% Passive Stake in Clovis Oncology

Financial news for CLVS dated on 2016-01-27: Clovis Oncology Initiates Immunotherapy Combination Trial

Financial news for CLVS dated on 2016-01-20: Credit Suisse Initiates Coverage on Clovis Oncology at Outperform, Announces \$32.00 PT

Financial news for CLVS dated on 2015-12-29: 10 Biotechs Short Sellers Are Betting Against

Financial news for CLVS dated on 2015-12-23: 6 Charts Costa Is Watching

Financial news for CLVS dated on 2015-12-17: Benzinga's Top Initiations

Financial news for CLVS dated on 2015-12-17: Janney Analyst Starts Clovis Oncology At Buy, Expects Regulatory Approvals Coming In 2016

Financial news for CLVS dated on 2015-12-17: Janney Capital Initiates Coverage on Clovis Oncology at Buy

Financial news for CLVS dated on 2015-12-15: Clovis Oncology Receives Notification of PDUFA Extension for Rociletinib

Financial news for CLVS dated on 2015-12-11: Vetr Crowd No Longer Uber-Bearish On Puma Biotech

Financial news for CLVS dated on 2015-12-01: Benzinga's M&A Chatter for Tuesday December 1, 2015

Financial news for CLVS dated on 2015-12-01: Hearing Unconfirmed Market Chatter of Potential Amgen Interest in Clovis

Financial news for CLVS dated on 2015-12-01: Option Alert: CLVS Dec15 \$30.0 Calls Sweep: 553 @ ASK \$2.90: 3118 traded vs 5293 OI: \$31.31 Ref

Financial news for CLVS dated on 2015-11-25: Shares of Clovis Oncology Spike \$2+; Hearing Kyle Bass Making Highly Bullish Comments on Name

Financial news for CLVS dated on 2015-11-25: Clovis Spikes Higher

Financial news for CLVS dated on 2015-11-25: Clovis Shares Spiking

Financial news for CLVS dated on 2015-11-23: Clovis Oncology Continues Lower After Consolidation

Financial news for CLVS dated on 2015-11-17: Morning Market Losers

Financial news for CLVS dated on 2015-11-17: Benzinga's Top Downgrades

Financial news for CLVS dated on 2015-11-17: Wallachbeth Downgrades Clovis Oncology to Hold

Financial news for CLVS dated on 2015-11-17: Benzinga's Top #PreMarket Losers

Financial news for CLVS dated on 2015-11-17: Goldman Sachs Downgrades Clovis Oncology to Neutral, Lowers PT to \$23.00

Financial news for CLVS dated on 2015-11-16: Mid-Afternoon Market Update: Dow Surges More Than 200 Points; Dillard's Shares Dip On Earnings Miss

Financial news for CLVS dated on 2015-11-16: Clovis Oncology Shares Unaffected Following Mid-Day Downgrade from Mizuho

Financial news for CLVS dated on 2015-11-16: Mid-Day Market Update: Starwood Drops Following Announcement of Acquisition Deal With Marriott; Sunoco Shares Gain

Financial news for CLVS dated on 2015-11-16: Clovis Oncology Plunges 70% In One Morning: What Happened?

Financial news for CLVS dated on 2015-11-16: What The FDA Gave Clovis Oncology In June 2013, It Has Taken Away

Financial news for CLVS dated on 2015-11-16: Mid-Morning Market Update: Markets Edge Higher; Marriott To Acquire Starwood Hotels For \$12.2B

Financial news for CLVS dated on 2015-11-16: Morning Market Losers

Financial news for CLVS dated on 2015-11-16: Clovis Oncology Shares Resume Trading Down 60% Following Report of FDA Request for Additional Information on Lung Cancer Drug

Financial news for CLVS dated on 2015-11-16: Clovis Oncology to Resume Trading at 8:30 AM ET

Financial news for CLVS dated on 2015-11-16: Clovis Oncology Announces Regulatory Update for Rociletinib NDA Filing

Financial news for CLVS dated on 2015-11-16: Shares of Clovis Oncology Halted News Pending

Financial news for CLVS dated on 2015-10-09: AstraZeneca Halts 2 Lung Cancer Drug Combo Trials

Financial news for CLVS dated on 2015-09-29: Clovis Oncology Announces U.S. and E.U. Regulatory Milestones for Rociletinib in the Treatment of Advanced EGFR-Mutant T790M+ Non-Small Cell Lung Cancer

Financial news for CLVS dated on 2015-09-14: Biotechs Coming Off One Of The Busiest Weeks In Recent Memory

Financial news for CLVS dated on 2015-09-08: Clovis Oncology Presentations for Tuesday September 8

Financial news for CLVS dated on 2015-09-04: Clovis Oncology Announces Data Presentations at 16th World Conference on Lung Cancer September 6-9, 2015

Financial news for CLVS dated on 2015-08-20: 10 Biotech Stocks With Catalysts Coming Soon

Financial news for CLVS dated on 2015-08-11: Clovis Oncology Reports Entering Into of Clinical Trial Collaboration with Roche's Genentech for Evaluation of COL-1686, MPDL3280A Combo

Financial news for CLVS dated on 2015-08-08: Clovis Oncology Could Pass \$100 By Year-End: Here's Why

Financial news for CLVS dated on 2015-08-06: Clovis Oncology Reports Q2 EPS of \$(2.10) vs \$(1.99) Est; Revenue of \$0.00

Financial news for CLVS dated on 2015-08-03: Clovis Oncology Completes US, EU Regulatory Submissions for Rociletinib for Treatment of Advanced EGFR-Mutant T790M+ NSCLC

Financial news for CLVS dated on 2015-07-20: Benzinga's Top Upgrades

Financial news for CLVS dated on 2015-07-20: Clovis Oncology, FibroGen Are Key Biotech Names For Goldman Sachs

Financial news for CLVS dated on 2015-07-20: Goldman Sachs Upgrades Clovis Oncology to Conviction Buy

Financial news for CLVS dated on 2015-07-10: Clovis Oncology Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock

Financial news for CLVS dated on 2015-07-08: Clovis Oncology Prices 3.525M Offering At \$78/Share

Financial news for CLVS dated on 2015-07-07: Clovis Oncology Announces \$275M Secondary Offering

Financial news for CLVS dated on 2015-07-01: Clovis Oncology Initiates Rolling NDA Submission to the FDA for Rociletinib in the Treatment of Advanced EGFR-Mutant Non-small Cell Lung Cancer

Financial news for CLVS dated on 2015-06-22: Clovis Oncology Appoints Dr. Lindsey Rolfe as Chief Medical Officer

Financial news for CLVS dated on 2015-06-01: 16 Biotech Stocks Moving Off The ASCO Conference

Financial news for CLVS dated on 2015-06-01: In CNBC Interview Clovis CEO Mahaffy Says Co. Will Apply For Lung Cancer Drug Approval In July, Expects Lung Drug To Come By End Of Year

Financial news for CLVS dated on 2015-06-01: Morning Market Losers

Financial news for CLVS dated on 2015-06-01: Benzinga's Top #PreMarket Losers

Financial news for CLVS dated on 2015-05-31: Clovis Oncology CO-1686 Phase 2 Study

Results Demonstrate Consistent and Promising Clinical Activity and Disease Control in Very Advanced Patients with EGFR-Mutant NSCLC

Financial news for CLVS dated on 2015-05-30: Clovis Oncology's Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Highly Compelling Clinical Activity at ASCO

Financial news for CLVS dated on 2015-05-15: Piper Jaffray Downgrades Clovis Oncology, Asks 'Point Of Maximal Optimism?'

Financial news for CLVS dated on 2015-05-14: Stifel Talks 5 Biotech Stocks

Financial news for CLVS dated on 2015-05-06: Clovis oncology Q1 EPS -\$1.86 vs -\$1.82 est

Financial news for CLVS dated on 2015-05-06: Goldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis Oncology

Financial news for CLVS dated on 2015-04-13: Benzinga's Volume Movers

Financial news for CLVS dated on 2015-04-13: Morning Market Gainers

Financial news for CLVS dated on 2015-04-13: Benzinga's Top Upgrades

Financial news for CLVS dated on 2015-04-13: Benzinga's Top #PreMarket Gainers

Financial news for CLVS dated on 2015-04-13: Goldman Just Raised Its Clovis Oncology Target ~50%, Upgrades To Buy

Financial news for CLVS dated on 2015-04-13: Goldman Sachs Upgrades Clovis Oncology To Buy

Financial news for CLVS dated on 2015-04-13: Goldman Sachs Upgrades Clovis Oncology to Buy, Raises PT to \$117.00

Financial news for CLVS dated on 2015-04-07: Benzinga's Volume Movers

Financial news for CLVS dated on 2015-04-07: Morning Market Gainers

Financial news for CLVS dated on 2015-04-07: Benzinga's Top #PreMarket Gainers

Financial news for CLVS dated on 2015-04-06: Clovis Oncology Given Breakthrough Therapy Designation for Rucaparib for Monotherapy Treatment of Advanced Ovarian Cancer in Patients with BRCA-mutated Tumors (Inclusive of both Germline and Somatic BRCA Mutations)

Financial news for CLVS dated on 2015-03-11: 18 Biotech Stocks These Wall Street Analysts Are Tracking

Financial news for CLVS dated on 2015-02-25: Clovis Oncology Reports Q4 EPS of \$(1.62)

Financial news for CLVS dated on 2015-02-25: Earnings Scheduled For February 25, 2015

Financial news for CLVS dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for CLVS dated on 2014-11-19: Morning Market Losers

Financial news for CLVS dated on 2014-11-19: Clovis Oncology Shares Trade Almost 9% Lower Premarket Following Mixed Report on CO-1686 Phase 2 Data

Financial news for CLVS dated on 2014-11-17: Clovis Oncology Enters Into Oncology Clinical Trial Collaboration With GlaxoSmithKline

Financial news for CLVS dated on 2014-11-07: UPDATE: Stifel Reiterates On Clovis Oncology Following 3Q14 LPS

Financial news for CLVS dated on 2014-11-07: Stifel Nicolaus Maintains Buy on Clovis Oncology, Inc., Raises PT to \$75.00

Financial news for CLVS dated on 2014-10-23: Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer

Financial news for CLVS dated on 2014-09-28: Clovis Oncology Announces Encouraging Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer

Financial news for CLVS dated on 2014-09-26: Clovis Oncology Spikes to High

Financial news for CLVS dated on 2014-09-03: Morning Market Losers

Financial news for CLVS dated on 2014-07-18: Biotech Enters Reporting Season With Large Caps Central To Sector Performance

Financial news for CLVS dated on 2014-06-23: US Stock Futures Flat Ahead Of Manufacturing PMI

Financial news for CLVS dated on 2014-06-23: Clovis Oncology Reports First Patient Enrolled in TIGER2 Study

Financial news for CLVS dated on 2014-06-05: Market Wrap For June 5: Markets Positive Before Friday's Employment Report

Financial news for CLVS dated on 2014-06-05: UPDATE: Stifel Upgrades Clovis Oncology On Favorable Risk/Reward

Financial news for CLVS dated on 2014-06-05: Stifel Nicolaus Upgrades Clovis Oncology, Inc. to Buy

Financial news for CLVS dated on 2014-06-04: Market Wrap For June 4: Markets Slightly Higher On Light Volume, Beige Book

Financial news for CLVS dated on 2014-06-04: Citi Downgrades Clovis, Rates It As High Risk

Financial news for CLVS dated on 2014-06-03: Market Wrap For June 3: Markets Run Out Of Steam

Financial news for CLVS dated on 2014-06-03: Mid-Day Market Movers For Tuesday, June 3, 2014

Financial news for CLVS dated on 2014-06-03: Stocks Hitting 52-Week Lows

Financial news for CLVS dated on 2014-06-03: Morning Market Losers

Financial news for CLVS dated on 2014-06-03: Benzinga's Top #PreMarket Losers

Financial news for CLVS dated on 2014-06-03: Citigroup Downgrades Clovis Oncology, Inc. to Neutral

Financial news for CLVS dated on 2014-06-02: Market Wrap For June 2: Dow, S&P Continue Rising, Nasdaq Slightly Lower

Financial news for CLVS dated on 2014-06-02: Mid-Afternoon Market Update; ISM Revised Twice, CONN Maintains Gains On Earnings Report

Financial news for CLVS dated on 2014-06-02: Mid-Day Market Update: MasTec Tumbles On Weak Forecast; Protective Life Shares Spike Higher

Financial news for CLVS dated on 2014-06-02: Mid-Morning Market Update: Markets Fall; Conn's Profit Beats Street View

Financial news for CLVS dated on 2014-06-02: Morning Market Losers

Financial news for CLVS dated on 2014-06-02: Benzinga's Top #PreMarket Losers

Financial news for CLVS dated on 2014-05-31: Clovis Presents Encouraging Data from Phase 1/2a Study Evaluating Lucitanib in Advanced Solid Tumors at ASCO

Financial news for CLVS dated on 2014-05-31: Clovis Oncology Presents Positive Phase 1/2 Rucaparib Results at ASCO

Financial news for CLVS dated on 2014-05-20: Morning Market Movers

Financial news for CLVS dated on 2014-05-20: Benzinga's Top #PreMarket Gainers

Financial news for CLVS dated on 2014-05-19: Clovis Oncology Reports Has Received Breakthrough Therapy Designation for CO-1686

Financial news for CLVS dated on 2014-05-15: Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss

Financial news for CLVS dated on 2014-05-15: Afternoon Market Movers

Financial news for CLVS dated on 2014-05-15: Mid-Afternoon Market Update: Markets Remain Red Despite Slight Recovery; Zendesk IPO Goes Off Without A Hitch

Financial news for CLVS dated on 2014-05-15: Mid-Day Market Update: Dow Drops Over 200 Points; Cisco Shares Jump On Upbeat Results



Financial news for CLVS dated on 2014-05-15: Benzinga's Volume Movers

Financial news for CLVS dated on 2014-05-15: Mid-Morning Market Update: Markets Tumble; Wal-Mart Posts Lower Profit

Financial news for CLVS dated on 2014-05-15: UPDATE: Clovis Oncology Shares Rise 15% Following Announcement of Presentation of Positive Data at ASCO

Financial news for CLVS dated on 2014-05-15: Morning Market Movers

Financial news for CLVS dated on 2014-05-15: Benzinga's Top #PreMarket Gainers

Financial news for CLVS dated on 2014-05-14: UPDATE: Clovis Oncology Shares Rise 8% After-Hours on Announcement of Presentation of Clinical Data at ASCO

Financial news for CLVS dated on 2014-05-08: Clovis Oncology, Inc. Reports Q1 EPS of \$(0.91) vs \$(0.85) Est; Revenue of \$13.60M

Financial news for CLVS dated on 2014-04-03: Foundation Medicine, Clovis Oncology Expand Collaboration

Financial news for CLVS dated on 2014-03-27: Benzinga's Volume Movers

Financial news for CLVS dated on 2014-03-27: Benzinga's Top #PreMarket Gainers

Financial news for CLVS dated on 2014-03-27: UPDATE: Clovis Oncology Shares Rise 12% Premarket on Positive Phase 1 Trial Results for NSCLC Treatment

Financial news for CLVS dated on 2014-03-27: US Stock Futures Rise; GDP, Jobless Claims Data In Focus

Financial news for CLVS dated on 2014-03-27: Clovis Oncology's CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival in Updated Phase 1 Study Results in Patients with NSCLC

Financial news for CLVS dated on 2014-03-26: Mid-Morning Market Update: Markets Open Higher; Francesca's Issues Downbeat Q1 Forecast

Financial news for CLVS dated on 2014-03-24: Benzinga's Top Initiations

Financial news for CLVS dated on 2014-03-24: Goldman Sachs Initiates Coverage on Clovis Oncology, Inc. at Neutral, Announces \$90.00 PT

Financial news for CLVS dated on 2014-02-27: Clovis Oncology, Inc. Reports Q4 EPS of \$(0.92) vs \$(0.78) Est

Financial news for CLVS dated on 2014-02-27: Clovis Oncology Expands CO-1686 Development Program

Financial news for CLVS dated on 2014-01-30: Clovis Oncology Says Earnings to be Released Toward End of February; Some Websites Show Company Reporting Today

Financial news for CLVS dated on 2014-01-13: Mid-Day Market Update: SodaStream Drops After Weak Outlook; Beam Shares Spike Higher

Financial news for CLVS dated on 2014-01-13: Mid-Morning Market Update: Markets Open Lower; Lululemon Lowers Q4 Outlook

Financial news for CLVS dated on 2014-01-13: Benzinga's Top #PreMarket Gainers

Financial news for CLVS dated on 2014-01-13: Clovis Oncology Announces 2014 Objectives, Financial Guidance

Financial news for CLVS dated on 2014-01-10: Clovis Shares Spike Higher After-Hours on CNBC Comments it is Next Intercept

Financial news for CLVS dated on 2013-12-23: US Stock Futures Rise Ahead Of Consumer Sentiment Data

Financial news for CLVS dated on 2013-12-23: Clovis Oncology CO-1686 Clinical Data Accepted as Oral Presentation at 2014 ELCC

Financial news for CLVS dated on 2013-12-02: Clovis Oncology Announces 2M Share Offering by Selling Stockholders

Financial news for CLVS dated on 2013-11-19: Benzinga's M&A Chatter for Tuesday November 19, 2013

Financial news for CLVS dated on 2013-11-19: Clovis Oncology Buys EOS SpA for Upfront Payment of \$190M in Stock, \$10M in Cash

Financial news for CLVS dated on 2013-11-19: Why Clovis Oncology Was The Short Trade Of The Day

Financial news for CLVS dated on 2013-11-15: UPDATE: H.C. Wainwright initiates on Clovis Oncology On Prospects Of CO-1686

Financial news for CLVS dated on 2013-11-15: HC Wainwright & Co. Initiates Coverage on Clovis Oncology, Inc. at Neutral, Announces \$55.00 PT

Financial news for CLVS dated on 2013-10-28: Mid-Morning Market Update: Markets Mixed; Merck Profit Beats Estimates

Financial news for CLVS dated on 2013-10-27: Clovis Oncology's CO-1686 Demonstrates Promising Clinical Activity and Safety in Phase I Study

Financial news for CLVS dated on 2013-10-21: QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations

Financial news for CLVS dated on 2013-09-30: Mid-Day Market Update: Dow Falls Over 100 Points; Active Network Shares Jump

Financial news for CLVS dated on 2013-09-30: Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net Profit Declines 7%

Financial news for CLVS dated on 2013-09-30: Shares of Clovis Oncology Down 4+% Following Mixed Ariad Data on AP26113, Data on AZD9291 from AstraZeneca

Financial news for CLVS dated on 2013-09-25: Mid-Day Market Update: US Stocks Turn Higher; MAKO Surgical Shares Surge On Acquisition News

Financial news for CLVS dated on 2013-09-25: Mid-Morning Market Update: Markets Slip; AutoZone Q4 Net Profit Rises 15%

Financial news for CLVS dated on 2013-09-25: Morning Market Losers

Financial news for CLVS dated on 2013-09-24: Benzinga's M&A Chatter for Tuesday September 24, 2013

Financial news for CLVS dated on 2013-09-24: Bloomberg Reporting Clovis Oncology Said to Get No Interest from Buyers

Financial news for CLVS dated on 2013-09-20: Benzinga's Top Initiations

Financial news for CLVS dated on 2013-09-20: Citigroup Initiates Coverage on Clovis Oncology, Inc. at Buy, Announces \$109.00 PT

Financial news for CLVS dated on 2013-09-17: Benzinga's M&A Chatter for Tuesday September 17, 2013

Financial news for CLVS dated on 2013-09-17: Clovis Oncology Spokesperson Says Company was Not Source of Bloomberg Article, Not Commenting on the Rumor

Financial news for CLVS dated on 2013-09-17: Shares of Clovis Resume Trade, Now Up 17%

Financial news for CLVS dated on 2013-09-17: Shares of Clovis Oncology Halted on Limit-Up, Limit-Down, Stock Halted Up 11%

Financial news for CLVS dated on 2013-09-17: Bloomberg Reporting Clovis Oncology Said to Weight Sale of \$2B Biotech Firm

Financial news for CLVS dated on 2013-09-06: UPDATE: Stifel Initiates Coverage on Clovis Oncology, Awaiting More Attractive Entry Point

Financial news for CLVS dated on 2013-09-06: Stifel Nicolaus Initiates Coverage on Clovis Oncology, Inc. at Hold

Financial news for CLVS dated on 2013-08-26: These ETFs House The Next Biotech Takeover Targets

Financial news for CLVS dated on 2013-08-01: Clovis Oncology, Inc. Reports Q2 EPS of \$(0.72) vs \$(0.65) Est

Financial news for CLVS dated on 2013-06-25: Mizuho Securities Initiates Coverage on Clovis Oncology, Inc. at Buy, Announces \$90.00 PT

Financial news for CLVS dated on 2013-06-18: UPDATE: Piper Jaffray Lowers PT on Clovis Oncology to Reflect Recent Financing

Financial news for CLVS dated on 2013-06-18: Piper Jaffray Maintains Overweight on Clovis Oncology, Inc., Lowers PT to \$87.00

Financial news for CLVS dated on 2013-06-13: Clovis Oncology Announces 2 New Board Members

Financial news for CLVS dated on 2013-06-13: Clovis Oncology Announces Full Exercise of Underwriters' Over-Allotment Option

Financial news for CLVS dated on 2013-06-12: Clovis Oncology Pricing 3.33M Share Offering at \$72/Share

Financial news for CLVS dated on 2013-06-10: A Peek Into The Market Before The Trading Starts

Financial news for CLVS dated on 2013-06-10: Clovis Oncology Announces \$170M Offering of Common Stock

Financial news for CLVS dated on 2013-06-07: Benzinga's Top Pre-Market Gainers

Financial news for CLVS dated on 2013-06-06: UPDATE: Piper Jaffray Upgrades Clovis Oncology to Overweight Following CO-1686 Data Presentation

Financial news for CLVS dated on 2013-06-06: Benzinga's Top Upgrades

Financial news for CLVS dated on 2013-06-06: Piper Jaffray Upgrades Clovis Oncology, Inc. to Overweight, Raises PT to \$100.00

Financial news for CLVS dated on 2013-06-04: This Stock Was Up More Than 100 Percent Monday

Financial news for CLVS dated on 2013-06-03: Market Wrap for Monday, June 3: Stocks Rise to Start Week

Financial news for CLVS dated on 2013-06-03: Mid-Afternoon Market Update: Markets Recovering; Pandora Falls in Anticipation of Apple's Streaming Radio

Financial news for CLVS dated on 2013-06-03: Afternoon Market Gainers

Financial news for CLVS dated on 2013-06-03: Mid-Day Market Update: Markets Turn Mixed, Colonial Properties Gains On Acquisition News

Financial news for CLVS dated on 2013-06-03: Benzinga's Volume Movers

Financial news for CLVS dated on 2013-06-03: BioMarin Shares Remain at Lows Despite Piper Jaffray Note Defending News of Clovis, Tesaro Data Updates at ASCO, Says BioMarin's BMN-673 'Looks Competitive;' Reiterates Overweight, \$70 Target

Financial news for CLVS dated on 2013-06-03: Morning Market Movers

Financial news for CLVS dated on 2013-06-03: Clovis Oncology's Rucaparib Shows Encouraging Results from Ongoing Phase I/II Study

Financial news for CLVS dated on 2013-05-07: JP Morgan Maintains Overweight on Clovis Oncology, Inc., Raises PT to \$45.00

Financial news for CLVS dated on 2013-03-11: UPDATE: J.P. Morgan Raises PT on Clovis Oncology on Growing Optimism

Financial news for CLVS dated on 2013-03-11: JP Morgan Maintains Overweight on Clovis Oncology, Inc., Raises PT to \$33.00

Financial news for CLVS dated on 2013-03-06: UPDATE: Piper Jaffray Initiates Clovis Oncology with Neutral Rating on Strong Valuation

Financial news for CLVS dated on 2013-03-05: Piper Jaffray Initiates Coverage on Clovis Oncology, Inc. at Neutral, Announces \$20.00 PT

Financial news for CLVS dated on 2012-11-12: Mid-Afternoon Market Update: Markets Near Flat; J.C. Penney Falling Further

Financial news for CLVS dated on 2012-11-12: Mid-Day Market Update: Markets Slow Their Rally; JC Penney Spikes Lower

Financial news for CLVS dated on 2012-11-12: Mid-Morning Market Update: Markets Continue Cautious Rally; Jefferies Acquired by Leucadia

Financial news for CLVS dated on 2012-11-12: Benzinga's Top Pre-Market Losers

Financial news for CLVS dated on 2012-11-12: Clovis Oncology Announces Negative Results from Pancreatic Cancer Study

Financial news for CLVS dated on 2012-11-05: Clovis Oncology Reports Q3 EPS \$-0.71 vs \$-0.67 Est

Financial news for CLVS dated on 2012-07-16: Clovis Oncology and Array BioPharma Announce Agreement to Discover Novel Mutant KIT Inhibitor

Financial news for CLVS dated on 2012-04-04: Clovis Oncology Announces Pricing of 3.75M Share Offering at \$20.00

Financial news for CLVS dated on 2012-03-23: Market Update

Financial news for CLVS dated on 2012-03-23: Clovis Oncology Announces Proposed Public Offering of \$75M Shares

Financial news for CLVS dated on 2012-01-19: Clovis Oncology Announces FDA Acceptance of Investigational New Drug Application for Oral EGFR Mutant-Selective Inhibitor CO-1686

Financial news for CLVS dated on 2012-01-18: End-of-Day Market Summary for January 18, 2012

Financial news for CLVS dated on 2012-01-18: Afternoon Movers; Markets Moved Higher

Financial news for CLVS dated on 2012-01-03: UPDATE: JP Morgan Initiates Clovis Oncology at Overweight

Financial news for CLVS dated on 2012-01-03: JP Morgan Initiates Clovis Oncology at Overweight

Financial news for CLVS dated on 2012-01-03: JP Morgan Initiates Clovis Oncology at Overweight